Advertisement

Glukose

  • M. Brado
  • A. Bierhaus
  • A. Clemens
  • K. Dugi
  • M. Haass
  • H.-P. Hammes
  • A. v. Herbay
  • M. Hofmann
  • B. Isermann
  • T. Kassessinoff
  • M. S. Klevesath
  • G. Klöppel
  • M. Morcos
  • P. P. Nawroth
  • R. Riedasch
  • P. Rösen
  • S. Schiekofer
  • P. Wahl
  • T. Weiss

Zusammenfassung

Die Regulation des Energiestoffwechsels ist ein komplexes Wechselspiel zwischen Hormonen, exogenen Nährstoffen und dem Austausch von Substraten mit dem Ziel, eine konstante und ausreichende Versorgung aller Organe des Körpers sicherzustellen. Insulin steuert sowohl in der Resorptions- wie in der Postresorptionsphase als Schlüsselhormon den Austausch und die Verteilung von Substraten. Glukagon, Cortisol, Katecholamine und das Wachstumshormon spielen eine wesentliche Rolle für den Energiestoffwechsel in Zeiten eines akuten Glukosebedarfs wie er bei Arbeitsbelastung, im Stress oder als Reaktion auf eine Hypoglykämie vorkommt. Wichtigste Organe für die Aufrechterhaltung der Energiehomöostase sind die Leber und die Niere aufgrund ihrer besonderen Fähigkeit, Glukose zu produzieren; das Gehirn, da es von Glukose als seinem wesentlichen Energiesubstrat abhängig ist; die Muskulatur und das Fettgewebe aufgrund ihrer Fähigkeit, auf Insulin zu reagieren und Glukose in Form von Glykogen und Fett zu speichern.

Literatur

Literatur zu Abschn. 16.1

  1. Ashcroft S.J., Ashcroft F.M. (1990) Properties and functions of ATP-sensitive K-channels. Cell Signal 2: 197.214PubMedCrossRefGoogle Scholar
  2. Ashcroft S.J.H. (1990) Glucoreceptor mechanisms and the control of insulin release and biosynthesis. Diabetologia 18: 5CrossRefGoogle Scholar
  3. Bliss M.T. (1982) The discovery of insulin. The University of Chicago Press, ChicagoCrossRefGoogle Scholar
  4. Boyle W.J., Smeal T., Defize L.H. et al. (1991) Activation of protein kinase C decreases phosphorylation of c-jun sites that negatively regulate its DNA-binding activity. Cell 64: 573Google Scholar
  5. Chan S.I., Keim P., Steiner D.F. (1976) Cell-free synthesis of rat preproinsulins: characterization and partial amino acid sequence determination. Proc Natl Acad Sci USA 73: 1964Google Scholar
  6. Clark A.R., Docherty K. (1992) The insulin gene. In: Ashcroft F.M., Ashcroft S.J. (eds) Insulin, Molecular Biology to Pathology. Oxford University Press, OxfordGoogle Scholar
  7. Conlon J.M., Samson W.K., Dobbs R.E. et al. (1979) Glukagon like polypeptides in canine brain. Diabetes 28: 700–702PubMedCrossRefGoogle Scholar
  8. Cook D.L., Haies C.N. (1984) Intracellular ATP directly blocks K+ channels in pancreatic B-cells. Nature 311: 271–273PubMedCrossRefGoogle Scholar
  9. Cook D.L., Satin L.S., Ashford M.L. et al. (1988) ATP-sensitive K+ channels in pancreatic B-cells: sphare channel hypo thesis. Diabetes 37: 495–498PubMedCrossRefGoogle Scholar
  10. Cook D.L., Taborsky G.J. (1997) B-cell function and insulin secretion. In: Porte D., Sherwin R.S. (eds) Ellenberg & Rifkin’s Diabetes mellitus. Appleton & Lange, Stamford, 5th edn, pp 49–73Google Scholar
  11. DeFronzo R.A. (1988) Lilly lecture 1987. The triumvirate: Betacell, muscle, liver: a collision responsible for NIDDM. Diabetes 37: 667–687PubMedGoogle Scholar
  12. Dent P., Lavoinne A., Narkielny S. et al. (1990) The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature 348: 302PubMedCrossRefGoogle Scholar
  13. Docherty K., Steiner D.F. (1997) Molecular and cellular biology of the β-cell. In: Porte D., Sherwin R.S. (eds) Ellenberg & Rifkin’s Diabetes mellitus. Appleton & Lange, Stamford, 5th edn, pp 29–48Google Scholar
  14. Fingar D.C., Birnbaum M.J. (1994) Characterization of the mitogen-activated pro tein kinase/90 kilodalton ribosomal protein S6 kinase signaling pathway in 3T3-L1 adipocytes and its role in insulin stimulated glucose transport. Endocrinology 134: 728PubMedCrossRefGoogle Scholar
  15. Han V.K., Hynes M.A., Jin C. et al. (1986) Cellular localisation of pro glucagon/glucagon like peptide I messenger RNA in rat brain. J Neuro Sci Res 11: 97–107CrossRefGoogle Scholar
  16. Holman G.D., Kasuga M. (1997) From receptor to transporter: insulin signalling to glucose transport. Diabetologia 40: 991–1003PubMedCrossRefGoogle Scholar
  17. Ingebritsen T.S., Stewart A.A., Cohen P. (1983) The protein phosphatases involved in cellular recognition. 6. Measurement of type-1 and type-2 protein phosphatases in extracts of mammalian tissues; an assessment of their physiological role. Eur J Biochem 132: 297PubMedCrossRefGoogle Scholar
  18. Jelinek L.I., Lok S., Rosenberg G.B. et al. (1993) Expression, cloning and signaling properties of the rat glucagon receptor. Science 259: 1614–1616PubMedCrossRefGoogle Scholar
  19. Jouneaux C., Audigier Y., Goldsmith P. et al. (1993) Gs mediates hormonal inhibition of the calcium pump in the liver plasma membrane. J Biol Chem 268: 2368–2372PubMedGoogle Scholar
  20. Jungermann K., Möhler H. (1980) Biochemie. Springer, Berlin Heidelberg New York TokyoCrossRefGoogle Scholar
  21. Kimball S.R., Vary T.C., Jefferson L.J. (1994) Regulation of protein synthesis by insulin. Ann Rev Physiol 56: 321CrossRefGoogle Scholar
  22. Klarlund J.K., Cherniack A.D., Conway B.R., VanRenterghem B., Czech M.P.: Mechanisms of insulin action. In: Porte D., Sherwin R.S. (eds) Ellenberg & Rifkin’s Diabetes mellitus. Appleton & Lange, Stamford, 5th edn, pp 75–93Google Scholar
  23. Lane M.A. (1907) The cytological characters of the areas of Langerhans. Am J Anat 7: 409–422CrossRefGoogle Scholar
  24. Lefebvre P.I., Luycks A.S. (1979) Glucagon and diabetes: a reappraisal. Diabetologia 16: 347–354PubMedCrossRefGoogle Scholar
  25. Lomedico P.T., Chan S.I., Steiner D.F. et al. (1977) Immunological and chemical characterization of bovine preproinsulin. J Biol Chem 252: 7971PubMedGoogle Scholar
  26. Philippe I., Missotten M. (1990) Functional characterisation of a cAMP-responsive element of the rat insulin I gene. J Biol Chem 8: 225Google Scholar
  27. Philippe J. (1991) Structure and pancreatic expression of the insulin and glucagon genes. Endocrine Rev 12: 252CrossRefGoogle Scholar
  28. Rasmussen H., Zawalih K.C., Ganesan S. et al. (1990) Physiology and pathophysiology of insulin secretion. Diabetes Care 13: 655–666PubMedCrossRefGoogle Scholar
  29. Ravazzola M., Ord L. (1980) Glucagon and glicentin immunoreactivity are topologically segregated in the α-granula of the human pancreatic A cell. Nature 284: 66–67PubMedCrossRefGoogle Scholar
  30. Redpath N.T., Proud C.G. (1994) Molecular mechanisms in the control of translation by hormones and growth factors. Biochim Biophys Acta 1220: 147PubMedCrossRefGoogle Scholar
  31. Saksela K., Makelöa T.P., Hughes K. et al. (1992) Activation of protein kinase C increases phosphorylation of the Lmyc trans-activator domain at a GSK-3 target site. Oncogene 7: 347PubMedGoogle Scholar
  32. Schroeder W.T., Lopez S.C., Harper M.E. et al. (1984) Localization of the human glucagon gene (GCG) to chromosome Segment 2136-37. Cytogenet Cell Genet 38: 76–79PubMedCrossRefGoogle Scholar
  33. Shulmann G.I., Barrett E.I., Sherwin R.S. (1997) Integrated fuel metabolism. In: Porte D., Sherwin R.S. (eds) Ellenberg & Rifkin’s Diabetes mellitus. Appleton & Lange, Stamford, 5th edn, pp 1–17Google Scholar
  34. Stein R. (1993) Factors regulating insulin gene transcription. Trends Endocrinol Metab 4: 96PubMedCrossRefGoogle Scholar
  35. Taeger H., Given B., Baldwin D. et al. (1979) A structurally abnormal insulin causing human diabetes. Nature 281: 122CrossRefGoogle Scholar
  36. Tillil H., Shapiro E.T., Miller M.A. et al. (1988) Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol S254: 349–357Google Scholar
  37. Tricolli H.A.V., Bell G.I., Shows T.B. (1984) The human glucagon gene is located on chromosome 2. Diabetes 33: 200–202CrossRefGoogle Scholar
  38. Ulirich A., Shine I., Chirgwin J. et al. (1977) Rat insulin genes: construction of plasmids containing the coding sequences. Science 196: 1313CrossRefGoogle Scholar
  39. Unger R.H., Ord L.: Glucagon. In: Porte D., Sherwin R.S. (eds) Ellenberg & Rifkin’s Diabetes mellitus. Appleton & Lange, Stamford, 5th edn, pp 115–139Google Scholar
  40. Walker M.D. (1990) Insulin gene regulation. In: Cuatrecasas P., Jacobs P. (eds) Handbook of experimental pharmacology. Springer, Berlin Heidelberg New York Tokyo, pp 92–93Google Scholar
  41. White M.F. (1997) The insulin signalling system and the IRS proteins. Diabetologia 40: S2–S17PubMedCrossRefGoogle Scholar

Literatur zu Abschn. 16.2

  1. Barnes P.I., Karin M. (1997) Nuclear Factor-KB-a pivotal transcription factor in chronic inflammatory dieseases. New Engl J Med 336: 1066–1071PubMedCrossRefGoogle Scholar
  2. Bierhaus A., Hofmann M., Ziegler R., Nawroth P.P. (1998) AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. Part I: The AGE-concept. Cardiovasc Res 37: 586–600PubMedCrossRefGoogle Scholar
  3. Fenner E., King G.L. (1997) Vascular dysfunction in diabetes mellitus. Lancet 350(Suppl. 1): 9–13CrossRefGoogle Scholar
  4. Giugliano D., Ceriello A., Paolisso G. (1995) Diabetes mellitus, hypertension and cardiovascular disease: which role for oxidative stress? Metabolism 44: 363–368PubMedCrossRefGoogle Scholar
  5. Halliwell B. (1993) The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 23 suppl I: 118–126Google Scholar
  6. Hunt J.V., Smith C.C.T., Wolff S.P. (1990) Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modifications. Diabetes 39: 1420–1424PubMedCrossRefGoogle Scholar
  7. King G.L., Brownlee M. (1996) The cellular and molecular mechanisms of diabetic complications. Endocrin Metabol 25: 255–270Google Scholar
  8. Schmidt A.M., Yan S.D., Stern D.M. (1995) The dark side of glucose. Nature Med 1: 1002–1004PubMedCrossRefGoogle Scholar
  9. Stehouwer C.D.A., Lambert I., Donker A.J.M., van Hinsbergh V.W.M. (1997) Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovascular Res 34: 55–68CrossRefGoogle Scholar
  10. Vlassara H., Bucala R., Striker L. (1994) Pathogenic effects of advanced glycosylation: biochemical, biological and clinical implications for diabetes and aging. Lab Invest 70: 138–151PubMedGoogle Scholar

Literatur zu Abschn. 16.3

  1. Amiel S.A. (1997) Hypoglycaemia in diabetes mellitus-protecting the brain. Diabetologia 40(Suppl 2): S62–68CrossRefGoogle Scholar
  2. Biggers D.W., Myers S.R., Neal D. et al. (1989) Role of brain in counterregulation of insulin-induced hypoglycemia in dogs. Diabetes 38(1): 7–16PubMedCrossRefGoogle Scholar
  3. Borg M.A., Sherwin R.S., Borg W.P., Tamborlane W.V., Shulman G.I. (1997) Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats. J Invest 99: 361–365CrossRefGoogle Scholar
  4. Boyle P.J. (1997) Alteration in brain glucose metabolism induced by hypoglycaemia in man. Diabetologia 40(Suppl 2): S69–74CrossRefGoogle Scholar
  5. Capella C., Heitz P.U., Hofler H., Solcia E., Kloppel G. (1995) Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 425(6): 547–560PubMedCrossRefGoogle Scholar
  6. Cersosimo E., Molina P.E., Abumrad N.N. (1997) Renal glucose production during insulin-induced hypoglycemia. Diabetes 46(4): 643–646)PubMedCrossRefGoogle Scholar
  7. Cersosimo E., Garlick P., Ferretti J. (2000) Renal substrate metabolism and gluconeogenesis du ring hypoglycemia in humans. Diabetes 49: 1186–1193PubMedCrossRefGoogle Scholar
  8. Clutter W.E., Rizza R.A., Gerich J.E., Cryer P.E. (1988) Regulation of glucose metabolism by sympathochromaffin catecholamines. Diabetes Metab Rev 4(1): 1–15PubMedCrossRefGoogle Scholar
  9. Correnti S., Liverani A., Antonini G., Paganelli M.T., Mercati U. (1996) Intraoperative ultrasonography for pancreatic insulinomas. Hepatogastroenterology 43(7): 207–211PubMedGoogle Scholar
  10. Debrah K., Sherwin R.S., Murphy J., Kerr D. (1996) Effect of caffeine on recognition of and physiological responses to hypoglycaemia in insulin-dependent diabetes. Lancet 347(8993): 19–24PubMedCrossRefGoogle Scholar
  11. De Feo P., Perriello G., Torlone E. et al. (1989) Contribution of cortisol to glucose counterregulation in humans. Am J Physiol 257(1 Pt 1): E35–42Google Scholar
  12. Del Prato S., Riccio A., Vigili de Kreutzenberg S, Dorella M., Avogaro A., Marescotti M.C., Tiengo A. (1993) Mechanisms of fasting hypoglycemia and concomitant insulin resistance in insulinoma patients. Metabolism 42(I): 24–29)PubMedCrossRefGoogle Scholar
  13. Folkman J., Watson K., Ingber D., Hanahan D. (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339(6219): 58–61PubMedCrossRefGoogle Scholar
  14. Gomez B., Garcia-Villallon A.L., Frank A., Garcia J.L., Monge L., Dieguez G. (1992) Effects of hypoglycemia on the cerebral circulation in awake goats. Neurology 42(4): 909–16PubMedCrossRefGoogle Scholar
  15. Hampton S.M., Beyzavi K., Teale D., Marks V. (1988) A direct assay for proinsulin in plasma and its applications in hypoglycaemia. Clin Endocrinol (Oxf) 29(1): 9–16CrossRefGoogle Scholar
  16. Herbay A., Sieg B., Schurmann G., Hofmann W.J., Betzler M., Otto H.F. (1991) Proliferative activity of neuroendocrine tumours of the gastroenteropancreatic endocrine system: DNA flow cytometric and immunohistological investigations. Gut 32(8): 949–953CrossRefGoogle Scholar
  17. Kisker O., Bartsch D., Weinel R.J., Joseph K., Welcke U.H., Zaraca F., Rothmund M. (1997) The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors. J Am Coll Surg 184(5):487–492PubMedGoogle Scholar
  18. Kubota A., Yamada Y., Kagimoto S. et al.(1994) Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93(3): 1321–1325PubMedCrossRefGoogle Scholar
  19. Maggs D.G., Borg W.P., Sherwin R.S. (1997) Microdialysis techniques in the study of brain and skeletal muscle. Diabetologia 40(Suppl 2): S75–82CrossRefGoogle Scholar
  20. Marks V., Rose F.C. (1981) Hypoglycemia. 2nd edn, Blackwell, OxfordGoogle Scholar
  21. McMahon M.M., O’Brien P.C., Service F.J. (1989) Diagnostic interpretation of the intravenous tolbutamide test for insulinoma. Mayo Clin Proc 64(12):1481–1488PubMedCrossRefGoogle Scholar
  22. Moertel C.G., Lefkopoulo M., Lipsitz S., Hahn R.G., Klaassen D. (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326(8): 519–523PubMedCrossRefGoogle Scholar
  23. Service F.J. (1995) Hypoglycemic disorders. N Engl J Med 332(17): 1144–1152PubMedCrossRefGoogle Scholar
  24. Service F.J., O’Brien P.C., Kao P.C., Young W.F. Jr (1992) C-peptide suppression test: effects of gender, age, and body mass index; implications for the diagnosis of insulinoma. J Clin Endocrinol Metab 74(1):204–210PubMedCrossRefGoogle Scholar
  25. Simpson I.A., Appel N.M., Hokari M., Oki J., Holman G.D., Maher F., Koehler-Stec E.M., Vannucci S.J., Smith Q.R. (1999) Bloodbrain barrier glucose transporter: effects of hypo-and hyperglycemia revisited. J Neurochem Jan; 72(1): 238–247CrossRefGoogle Scholar
  26. Towler D.A., Havlin C.E., Craft S., Cryer P. (1993) Mechanism of awareness of hypoglycemia. Diabetes 42: 1791–1798PubMedCrossRefGoogle Scholar

Literatur zu Abschn. 16.4

  1. Albers N., Lohr M., Bogner U., Loy V., Kloppel G. (1989) Nesidioblastosis of the pancreas in an adult with persistent hyperinsulinemic hypoglycemia. Am J Clin Pathol 91(3): 336–340PubMedGoogle Scholar
  2. Bas F., Darendeliler F., Demirkol D., Bundak R., Saka N., Gunoz H. (1999) Successful therapy with calcium channel blocker (nifedipine) in persistent neonatal hyperinsulinemic hypoglycemia of infancy. J Pediatr Endocrinol Metab 12(6): 873–878PubMedCrossRefGoogle Scholar
  3. Bell D.S., Grizzle W.E., Dunlap N.E. (1995) Nesidioblastosis causing reversal of insulin-dependent diabetes and developme nt of hyperinsulinemic hypoglycemia. Diabetes Care 18(10): 1379–1380PubMedGoogle Scholar
  4. Cersosimo E., Molina P.E., Abumrad N.N.: Renal glucose production during insulin-induced hypoglycemia. Diabetes 46(4): 643–646Google Scholar
  5. Dunne M.I., Kane C., Shepherd R.M. et al. (1997) Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor. N Engl J Med 336(10): 703–706PubMedCrossRefGoogle Scholar
  6. Elias A.N., Gwinup G. (1982) Glucose-resistant hypoglycemia in inanition. Arch Intern Med 142(4): 743–746PubMedCrossRefGoogle Scholar
  7. Fischer K.F., Lees J.A., Newman J.H. (1986) Hypoglycemia in hospitalized patients. Causes and outcomes. N Engl J Med 315(20): 1245–1250PubMedCrossRefGoogle Scholar
  8. Goossens A., Gepts W., Saudubray J.M., et al. (1989) Diffuse and focal nesidioblastosis. Am J Surg Pathol 13: 766–775PubMedCrossRefGoogle Scholar
  9. Hasler W.L., Soudah H.C., Owyang C. (1996) Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome. J Pharmacol Exp Ther 277(3): 1359–1365PubMedGoogle Scholar
  10. Hogan M.I., Service F.J., Sharbrough F.W., Gerich J.E. (1983) Oral glucose tolerance test compared with a mixed meal in the diagnosis of reactive hypoglycemia. A caveat on stimulation. Mayo Clin Proc 58(8): 491–496PubMedGoogle Scholar
  11. Johnson D.D., Dorr K.E., Swenson W.M., Service F.J. (1980) Reactive hypoglycemia. JAMA 243(11): 1151–1155PubMedCrossRefGoogle Scholar
  12. Kolaczynski J.W., Ylikahri R., Harkonen M., Koivisto V.A. (1988) The acute effect of ethanol on counterregulatory response and recovery from insulin-induced hypoglycemia. J Clin Endocrinol Metab 67(2): 384–388PubMedCrossRefGoogle Scholar
  13. Lecavalier L., Bolli G., Cryer P., Gerich J. (1989) Contributions of gluconeogenesis and glycogenolysis during glucose counterregulation in normal humans. Am J Physiol 256(6 Pt 1): E844–51Google Scholar
  14. Lee M.D., Zentella A., Vine W., Pekala P.H., Cerami A. (1987) Effect of endotoxin-induced monokines on glucose metabolism in the muscle celliine L6. Proc Natl Acad Sci USA 84(9): 2590–4–259PubMedCrossRefGoogle Scholar
  15. Le Roith D. (1997) Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 336(9): 633–640PubMedCrossRefGoogle Scholar
  16. Marks V., Teale J.D. (1999) Drug-induced hypoglycemia. Endocrinol Metab Clin North Am 28(3): 555–577PubMedCrossRefGoogle Scholar
  17. Palardy J., Havrankova J., Lepage R., Matte R., Belanger R., O’Amour P., Ste-Marie L.G. (1989) Blood glucose measurements during symptomatic episodes in patients with suspected postprandial hypoglycemia. N Engl J Med 321(21): 1421–1425PubMedCrossRefGoogle Scholar
  18. Pandit M.K., Burke J., Gustafson A.B., Minocha A., Peiris A.N. (1993) Drug-induced dis orders of glucose tolerance. Ann Intern Med 118(7): 529–539PubMedCrossRefGoogle Scholar
  19. Ron D., Powers A.C., Pandian M.R., Godine J.E., Axelrod L. (1989) Increased insulin-like growth factor II production and consequent suppression of growth hormone secretion: a dual mechanism for tumor-induced hypoglycemia. J Clin Endocrinol Metab 68(4): 701–706PubMedCrossRefGoogle Scholar
  20. Seckl M.I., Mulholland P.I., Bishop A.E., Teale J.O., Haies C.N., Glaser M., Watkins S., Seckl J.R. (1999) Hypoglycemica due to an insulin-secreting small-cell careinoma of the cervix. N Engl J Med 341(10): 733–736PubMedCrossRefGoogle Scholar
  21. Sempoux C., Poggi F., Brunelle F., Saudubray J.M., Fekete C., Rahier J. (1995) Nesidioblastosis and persistent neonatal hyperinsulinism. Diabete Metab 21(6): 402–407PubMedGoogle Scholar
  22. Shapiro E.T., Bell G.I., Polonsky K.S., Rubenstein A.H., Kew M.C., Tager H.S. (1990) Tumor hypoglycemia: relationship to high molecular weight insulin-like growth factor-II. J Clin Invest 85(5): 1672–1679PubMedCrossRefGoogle Scholar
  23. Teale J.O., Marks V. (1998) Glucocorticoid therapy suppresses abnormal secretion of big IGF-II by non-islet cell tumours inducing hypoglycaemia. Clin Endocrinol (Oxf) 49(4): 491–498CrossRefGoogle Scholar
  24. Thomas P.M. (1997) Current Opinion in Endocrinology and Diabetes 4. pp 272–276CrossRefGoogle Scholar
  25. Wal van der B.C., de Krijger R.R., de Herder W.W., Kwekkeboom D.J., van der Harn F., Bonjer H.J., van Eijck C.H. (2000) Adult hyperinsulinemic hypoglycemia not caused by an insulinoma: a report of two cases. Virchows Arch 436(5): 481–486PubMedCrossRefGoogle Scholar
  26. Wasada T., Hizuka N., Yamamoto M. et al. (1992) An insulin-like growth factor II-producing histiocytoma associated with hypoglycemia: analysis of the peptide, its gene expression, and glucose transporter isoforms. Metabolism 41(3): 310–316PubMedCrossRefGoogle Scholar
  27. Wilkin T.J., Hammonds P., Mirza I., Bone A.J., Webster K. (1988) Graves’ disease of the beta cell: glucose dysregulation due to islet-cell stimulating antibodies. Lancet 2(8621): 1155–1158PubMedCrossRefGoogle Scholar

Literatur zu Abschn. 16.5

  1. Arden C., Toeller M., Schumacher W., Heitkamp G., Gries F.A. (1997) Aspekte der Lebensqualität bei Typ-1-Diabetikern der Düsseldorfer EURODIAB-Stichprobe. Diab Stoffw 6: 189–198Google Scholar
  2. Assal J.P., Aoki T.T., Manzano F.M., Kozak G.P. (1974) Metabolic effects of sodium bicarbonate in management of diabetic ketoacidosis. Diabetes 23: 405–411PubMedGoogle Scholar
  3. Atkinson M.A., Bowman M.A., Campbell L., Darrow B.L., Kaufman D.L., Maclaren N.K. (1994) Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes (see comments). J Clin Invest 94: 2125–2129PubMedCrossRefGoogle Scholar
  4. Awata T., Kurihara S., Iitaka M., Takei S-I., Inoue I., Ishii C., Negishi K., Izumida T., Yoshiba Y., Hagura R., Kuzuya N., Kanazawa Y., Katayama S. (1998) Association of CTLA-4 gene A-G polymorphism (IDDM 12 locus) with acute-onset and insulin-depleted IDDM as weil as autOImmune disease (Graves’ disease and Hashimoto’s thyreoiditis) in the japanese population. Diabetes 47: 128–129.PubMedGoogle Scholar
  5. Barnett A.H., Epp C., Leslie R.D.G., Pyke D.A. (1981) Diabetes in identical twins. A study of 200 pairs. Diabetologia 20: 87–93PubMedCrossRefGoogle Scholar
  6. Bell G.I., Horita S., Karam J.H. (1984) A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 33: 176–183PubMedCrossRefGoogle Scholar
  7. Bennett S.T., Lucassen A.M., Gough S.C., Powell E.E., Undlien D.E., Pritchard L.E., Merriman M.E., Kawaguchi Y., Dronsfield M.J., Pociot F. et al. (1995) Susceptibility to human type 1 diabetes at !DDM 2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet 9: 284–292PubMedCrossRefGoogle Scholar
  8. Bingley P.J., Christie M.R., Bonifacio E. et al. (1994) Combined analysis of autoantibodles Improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 43: 1304–1310PubMedCrossRefGoogle Scholar
  9. Bode B.W., Steed R.D., Davidson P.C. (1996) Reduction in servere hypoglycemia with long-term continous subcutanous insulin infusion in type I diabetes. Diabetes Care 19: 324–327PubMedCrossRefGoogle Scholar
  10. Cavan D.A., Penny M.A., Bain S.C., Barnett H.A. Alberti K.G.M.M., Zimmet P., De Fronzo R.A., Keen H. (eds) (1997) International Textbook of Diabetes mellitus. 6, Molecular genetics of Typ-1-Diabetes mellitus. Chichester: John Wiley pp 109–124Google Scholar
  11. Charron-Prochownik D., Maihle T., Siminerio L., Songer T. (1997) Outpatient versus inpatient ca re of children newly diagnosed with IDDM. Diabetes Care 20: 657–660PubMedGoogle Scholar
  12. Cheetham T.D., Jones I., Taylor A.M., Holly J., Matthews D.R., Dunger D.B. (1993) The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents wlth type 1 (Insulin-dependent) diabetes mellitus. Diabetologia 36: 678–681PubMedCrossRefGoogle Scholar
  13. Christie M.R., Tun R.Y., Lo S.S. et al. (1992) Antibodies to GAD and tryptic fragments of islet 64 Kantigen as distinct markers for development of IDDM. Studies with identical twins. Diabetes 41: 782–787PubMedCrossRefGoogle Scholar
  14. Conrad B., Weidmann E., Trucco G. et al. (1994) Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature 371: 351–355PubMedCrossRefGoogle Scholar
  15. Conrad B., Weissmahr R.N., Boni I., Arcari R., Schupbach I., Mach B. (1997) A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell 90: 303–313PubMedCrossRefGoogle Scholar
  16. Copeman J.B., Cucca F., Hearne C.M. et al. (1995) Linkage disequilibrium mapping of a type 1 diabetes suspectibility gene (IDDM 7) to chromosome 2q31-q33. Nature Genet 9: 80–85PubMedCrossRefGoogle Scholar
  17. Dahlquist G. (1993) Etiological aspects of insulin-dependent diabetes mellitus: an epidemiological perspective. Autoimmunity 15: 61–65PubMedCrossRefGoogle Scholar
  18. Davies J.L., Cucca F., Goy J.V. et al. (1996) Saturation multipoint linkage mapping of chromosome 6q in type 1 diabetes. Hum Mol Genet 5: 1071–1074PubMedCrossRefGoogle Scholar
  19. De Filippo G., Carel J.C., Boitard C., Bougneres P.F. (1996) Longterm results of early cyclosporin therapy in juvenile IDDM. Diabetes 45: 101–104PubMedCrossRefGoogle Scholar
  20. Dobersen M.I., Scharff J.E., Ginsberg-Fellner F., Notkins A.L. (1980) Cytotoxic autoantibodies to beta cells in the serum of patients with insulin-dependent diabetes mellitus. N Engl J Med 303: 1493–1498PubMedCrossRefGoogle Scholar
  21. Dunn F., Nathan D.M., Scavini M., Selam I., Wingrove T.G. (1997) Long-term therapy of IDDM with an implantable insulin pumpe. Diabetes Care 20: 59–63.PubMedCrossRefGoogle Scholar
  22. Eisenbarth G.S., Morris M.A., Scearce R.M. (1981) CytOtoxic autoantibodies to cloned rat islet cells in serum of patients with diabetes mellitus. J Clin Invest 67: 403–408PubMedCrossRefGoogle Scholar
  23. Elliott R.B., Pilcher C.C., Fergusson D.M., Steward A.W. (1996) A population based strategy to prevent insulin-dependent diabetes using nicotin amide. J Pediatr Endocrinol Metab 9: 501–509PubMedCrossRefGoogle Scholar
  24. Faich G.A., Fishbein H.A., Ellis S.E. (1983) The epidemiology of diabetic acidosis: a population-based study. Am J Epidemiol 117: 551–558PubMedGoogle Scholar
  25. Feutren G., Papotz L., Assan R. et al. (1986) Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre doubleblind trail. Lancet 2: 119–124PubMedCrossRefGoogle Scholar
  26. Foulis A.K., McGill M., Farquharson M.A., Hilton D.A. (1997) A search for evidence of viral infection in pancreases of newly diagnosed patients with IDDM. Diabetologia 40: 53–61PubMedCrossRefGoogle Scholar
  27. Gallwitz B., Schmidt W.E. (1997) Insulinanaloga und neue Antidiabetika: Perspektiven der Diabetestherapie. Internist 38: 617–624PubMedCrossRefGoogle Scholar
  28. Gimeno S.G.A., DeSouza J.M.P. (1997) IDDM and milk consumption. A case-control study in Sao Paulo, Brazil. Diabetes Care 20: 1256–1260PubMedCrossRefGoogle Scholar
  29. Gorsuch A.N., Spencer K.M., Lister I., Wolf E, Bottazzo G.F., Cudworth A.G. (1982) Can future type 1 diabetes be predicted? A study in families of affected children. Diabetes 31: 862–866PubMedCrossRefGoogle Scholar
  30. Harrison L.C., Colman P.G., Dean B., Baxter R., Martin F.I. (1985) Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 34: 1306–1308PubMedCrossRefGoogle Scholar
  31. Hashimoto L., Habita C., Beressi J.P. et al. (1994) Genetic mapping of a susceptibility locus for insulin-dependent diabetes mellitus on chromosome 11q. Nature 371: 161–164PubMedCrossRefGoogle Scholar
  32. Hering B.I., Browatzki C.C., Schultz A.O., Bretzel R.G., Federlin K. (1994) Islet transplant registry report on adult and fetal islet allografts. Transplant Proc 26: 565–568PubMedGoogle Scholar
  33. Herskowitz R.D., Jackson R.A., Soeldner J.S., Eisenbarth G.S. (1989) Pilot trial to prevent type I diabetes: progression to overt IDDM despite oral nicotinamide. J Autoimmun 2: 733–737PubMedCrossRefGoogle Scholar
  34. Hitman G.A., Tarn A.C., Winter R.M. et al. (1985) Type 1 (insulindependent) diabetes and a highly variable locus dose to the insulin gene on chromosome 11. Diabetologia 28: 218–222PubMedCrossRefGoogle Scholar
  35. Holleman F., Hoekstra J.B.L. (1997) Insulin Lispro. N Engl J Med 337: 176–183PubMedCrossRefGoogle Scholar
  36. Hyöty H., Hiltunen M., Reuanen A. et al. (1993) Decline of mumps antibodies in Type 1(insulin-dependent) diabetic children and a plateau in the rising incidence of Type 1 diabetes after introduction of the mumps-measles-rubella vaccine in Finland. Diabetologia 36: 1303–1308PubMedCrossRefGoogle Scholar
  37. Jaremko J., Rorstad O. (1998) Advances toward the implantable artificial pancreas for treatment of diabetes. Diabetes Care 21: 444–450PubMedCrossRefGoogle Scholar
  38. Kahaly G., Förster G., Otto E., Hansen C., Schulz G. (1997) Diabetes mellitus Typ 1 als Teil des polyglandulären Autoimmunsyndroms. Diab Stoffw 6: 19–27Google Scholar
  39. Karjalainen J., Martin J.M., Knip M. et al. (1992) A bovine albumine peptide as a possible trigger of insulin-dependent diabetes mellitus. N Engl J Med 327: 302–307PubMedCrossRefGoogle Scholar
  40. Karounos D.G., Wolinsky J.S., Thomas J.W. (1993) Monoclonal antibody to rubella virus capsid protein recognizes a β-cell antigen. J Immunol 150: 3080–3085PubMedGoogle Scholar
  41. Katz J.D., Benoist C., Mathis D. (1995) T helper cell subsets in insulin-dependent diabetes. Science 268: 1185PubMedCrossRefGoogle Scholar
  42. Keller R.J., Eisenbarth G.S., Jackson R.A. (1993) Insulin prophylaxis in individuals at high risk of type I diabetes (see comments). Lancet 341: 927–928PubMedCrossRefGoogle Scholar
  43. Klöppel G., Clemens A. (1996) [Insulin-dependent diabetes mellitus. Current aspects of morphology, etiology and pathogenesis] Insulinabhängiger Diabetes mellitus. Aktuelle Aspekte zur Morphologie, Atiologie und Pathogenese. Pathologe 17: 269–275Google Scholar
  44. Kuzuya H., Matsuura N., Sakamoto M. et al. (1993) Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 42: 696–705PubMedCrossRefGoogle Scholar
  45. Kwok W.W., Mickelson E., Masewicz S., Milner E.C., Hansen J., Nepom G.T. (1990) Polymorphic DQ alpha and DQ beta interactions dictate HLA class II determinants of allo-recognition. J Exp Med 171: 85–95PubMedCrossRefGoogle Scholar
  46. Lampeter E.F., Homberg M., Quabeck K. et al. (1993) Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 341: 1243–1244PubMedCrossRefGoogle Scholar
  47. Leslie R.D., Pyke D.A., Denman A.M. (1985) Immunosupressive therapy in diabetes [letter]. Lancet 1: 516PubMedCrossRefGoogle Scholar
  48. Libman I., Songer T., LaPorte R. (1993) How many people in USA have IDDM? Diabetes Care 16: 841–842PubMedGoogle Scholar
  49. Löhr M., Klöppel G. (1987) Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia 30: 757–762PubMedCrossRefGoogle Scholar
  50. Ludvigsson J., Heding L., Lieden G., Marner B., Lernmark A. (1983) Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J Clin Res 286: 176–178CrossRefGoogle Scholar
  51. Mandrup Poulsen T, Reimers J.I., Andersen H.U., Pociot F., Karlsen A.E., Bjerre U., Nerup J. (1993) Nicotinamide treatment in the prevention of insulin-dependent diabetes mellitus. Diabetes Metab Rev 9: 295–309Google Scholar
  52. Martin S., Schernthaner G., Nerup J. et al. (1991) Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects. Diabetologia 34: 429–434PubMedCrossRefGoogle Scholar
  53. Mathieu C., Laureys J., Sobis H., Vandeputte M., Waer M., Bouillon R. (1992) 1,25-Dihydroxyvitamin D3 prevents ins ulitis in NOD mice. Diabetes 41: 1491–1495PubMedCrossRefGoogle Scholar
  54. Mathieu E., Fain O., Sitbon M., Thomas M. (1995) [Autoimmune diabetes after treatment with interferon-alpha (letter)] Diabète auto-immun après traîtement par interféron alpha. Presse Med 24: 238PubMedGoogle Scholar
  55. McGinnis R.E., Spielman R.S. (1995) Insulin expression: is VNTR allele 698 really anomalous? Nature Genet 10: 378–380PubMedCrossRefGoogle Scholar
  56. Meloni T., LaVecchia C., Marinaro A.M., Negri E., Mannazzu M.C., Colombo C., Ogana A. (1997) IDDM and early infant feeding. Sardinian case-control study. Diabetes Care 20: 340–342PubMedCrossRefGoogle Scholar
  57. Merriman T., Twells R., Merriman M. et al. (1997) Evidence by allelic association-dependent methods for a type 1 diabetes polygene (IDDM 6) on chromosome 18q21. Hum Mol Genet 6: 1003–1010PubMedCrossRefGoogle Scholar
  58. Millward B.A., Alviggi L., Hoskins P.J. et al. (1986) Immune changes associated with insulin dependent diabetes may remit without causing the disease: a study in identical twins. Br Med J 292: 793–796CrossRefGoogle Scholar
  59. Morahan G., Huang D., Tait B.D., Colman P.G., Harrison L.C. (1996) Markers on distal chromosome 2q linked to insulin-dependent diabetes mellitus. Science 272: 1811–1813PubMedCrossRefGoogle Scholar
  60. Moritani M., Yoshimoto K., Li S. et al. (1996) Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for auto immune diabetes. J Clin Invest 98: 1851–1859PubMedCrossRefGoogle Scholar
  61. Muir A., Schatz D., Maclaren N. (1993) Antigen-specific immunotherapy: oral tolerance and subcutaneous immunisation in the treatment of insulin-dependent diabetes. Diabetes Metab Rev 9: 279–287PubMedCrossRefGoogle Scholar
  62. Neu A., Hub R., Kehrer M., Ranke M.B. (1997) Incidence of IDDM in German Children Aged 0-14 Years. A 6-year population-based study (1987-1993). Diabetes Care 20: 530–533PubMedCrossRefGoogle Scholar
  63. Olmos P., A’Hern R., Heaton D.A., Millward B.A., Risley D., Pyke D.A., Leslie R.D. (1988) The significance of the concordance rate for type 1 (insulin-dependent) diabetes in identical twins. Diabetologia 31: 747–750PubMedCrossRefGoogle Scholar
  64. Owerbach D., Gabbay K.H. (1996) The Search for IDDM Suspetibility Genes. The Next Generation. Diabetes 45: 544–551PubMedCrossRefGoogle Scholar
  65. Padaiga Z., Tuomilehto J., Karvonen M. et al. (1997) Incidence trends in childhood onset IDDM in four countries around the Baltic sea during 1983-1992. Diabetologia 40: 187–192PubMedCrossRefGoogle Scholar
  66. Pietropaolo M., Castano L., Babu S. et al. (1993) Islet cell autoantigen 69 kD (ICA69). Molecular cloning and characterization of a novel diabetes-associated autoantigen. J Clin Invest 92: 359–371PubMedCrossRefGoogle Scholar
  67. Pietropaolo M., Trucco M. (1996) Viral elements in autoimmunity of Typ-1-Diabetes. T E M 7: 139–144Google Scholar
  68. Pociot F., Nerup J. (1993) A chromosome 2 suspectibility marker in familial IDDM: the IL-1 receptor antagonist. Diabetologia 36: A17CrossRefGoogle Scholar
  69. Pozzilli P., Visalli N., Cavallo M.G. et al. (1997) Vitamin E and nicotin amide have similar effects in maintaining residual β-cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study). Eur J Endocrinology 137: 234–239CrossRefGoogle Scholar
  70. Püschel K., Lockemann U., Saukko P., Klöppel G., Eisenmenger W. (1996) Scharlatanerie mit tödlichem Ausgang. Münch Med Wochenschr 138: 287–290Google Scholar
  71. Quattrin T., Thrailkill K., Baker L. et al. (1997) Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile. Diabetes Care 20: 374–380PubMedCrossRefGoogle Scholar
  72. Rabinovitch A. (1994) Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes 43: 613–621PubMedCrossRefGoogle Scholar
  73. Rapoport M.J., Jaramillo A., Zipris D. et al. (1993) Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 178: 87–99PubMedCrossRefGoogle Scholar
  74. Roep B.O. (1996) T-cell responses to autoantigens in IDDM. The search for the Holy Grail. Diabetes 45: 1147–1156PubMedCrossRefGoogle Scholar
  75. Roep B.O., Duinkerken G., Schreuder G.M., Kolb H., de Vries R.R., Martin S. (1996) HLA-associated inverse correlation between T cell and antibody responsiveness to islet autoantigen in recent-onset insulin-dependent diabetes mellitus. Eur J Immunol 26: 1285–1289PubMedCrossRefGoogle Scholar
  76. Rowe R.E., Wapelhorst B., Bell G.I., Risch N., Spielman R.S., Concannon P. (1995) Linkage and association between insulindependent diabetes mellitus (IDDM) suspectibility and markers near the glukokinase gene on chromosome 7. Nature Genet 10: 240–242PubMedCrossRefGoogle Scholar
  77. Schiel R., Müller U.A., Kalbas B., Franke I. (1996) Diabeteswissen und Lebensqualität zweier Patientengruppen mit intensivierter konventioneller Insulintherapie. Diab Stoffw 5: 63–68Google Scholar
  78. Schrezenmeir I., Laue C. (1996) Aktuelle Aspekte der Inseltransplantation. Med Klin 91: 19–24Google Scholar
  79. Scott C.R., Smith J.M., Cradock M.M., Pihoker C. (1997) Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. Pediatrics 100: 84–91PubMedCrossRefGoogle Scholar
  80. Secchi A., Socci C., Maffi P. et al. (1997) Islet transplantation in IDDM patients. Diabetologia 40: 225–231PubMedCrossRefGoogle Scholar
  81. Shamis I., Goldsang G., Gordon O., Laron Z., Albag Y. (1997) Ethnic differences in the incidence of childhood IDDM in Israel (1965-1993). Marked increase since 1985, especially in Yemenite Jews. Diabetes Care 20: 504–508PubMedCrossRefGoogle Scholar
  82. Shehadeh N., Calcinaro F., Bradley B.I., Bruchlim I., Vardi P., Lafferty K.J. (1994) Effect of adjuvant therapy on development of diabetes in mouse and man (see comments). Lancet 343: 706–707PubMedCrossRefGoogle Scholar
  83. Sibley R.K., Sutherland D.E.R., Goetz F.C., Michael A.F. (1985) Recurrent diabetes mellitus in the pancreatic iso-and allograft period. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 53: 132–144PubMedGoogle Scholar
  84. Silverstein I., Maclaren N., Riley W., Spillar R., Radjenovic D., Johnson S. (1988) Immunosupression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 319: 599–604PubMedCrossRefGoogle Scholar
  85. Skyler J.S., Lorenz T.I., Schwartz S. et al. (1993) Effects of an ant-CD5 immunoconjugate (CD5-plus) in re cent onset type I diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project Team. J Diabetes Complications 7: 224–232PubMedCrossRefGoogle Scholar
  86. Snorgaard O., Eskildsen P.C., Vadstrup S., Nerup J. (1989) Diabetic ketoacidosis in Denmark: epidemiology, ineidence rates, preeipitating factors and mortality rates. J Int Med 226: 223–228CrossRefGoogle Scholar
  87. Solimena M., Folli F., Aparisi R., Pozza G., De Camilli P. (1990) Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 322: 1555–1560PubMedCrossRefGoogle Scholar
  88. Steiner D.F., James D.E. (1992) Cellular and molecular biology of the beta cell. Diabetologia 35(Suppl. 2): S41–S48CrossRefGoogle Scholar
  89. Sutherland D.E., Gruessner A., Moudry Munns K. (1991) Report on results of pancreas transplantation in the United States October 1987 to October 1991 from the United Network for Organ Sharing Registry. Clin Transplant 5: 31–38Google Scholar
  90. The Diabetes Control And Complications Trail Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986CrossRefGoogle Scholar
  91. The Expert Commitee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Commitee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20: 1183–1197Google Scholar
  92. Thomson G., Robinson W.P., Kuhner M.K. et al. (1988) Genetic heterogeneity, modes of inheritance, and risk estimates for a joint study of Caucasians with insulin-dependent diabetes mellitus. Am J Hum Genet 43: 799–816PubMedGoogle Scholar
  93. Tiedge M., Hohne M., Lenzen S. (1993) Insulin secretion, insulin content and glucose phosphorylation in RINm5F insulinoma cells after transfection with human GLUT2 glucose-transporter cDNA. Biochem J 296: 113–118PubMedGoogle Scholar
  94. Tillil H., Kobberling J. (1987) Age-corrected empirical genetic risk estimates for first-degree relatives of IDDM patients. Diabetes 36: 93–99PubMedCrossRefGoogle Scholar
  95. Tyden G., Tibell A., Sandberg I., Brattstrom C., Groth C.G. (1996) Improved results with a simplified technique for pancreaticoduodenal transplantation with enteric exocrine drainage. Clin Transplant 10: 306–309PubMedGoogle Scholar
  96. Vague P., Picq R., Bernal M., Lassmann Vague V, Vialettes B. (1989) Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients. Diabetologia 32: 316–321Google Scholar
  97. Verge C.F., Gianani R., Kawasaki E. et al. (1996) Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45: 926–933PubMedCrossRefGoogle Scholar
  98. Vialettes B., Schmitt N., Hirn M. et al. (1991) The soluble receptor of interleukin 2 is not a serum marker of the autoimmune activity in type I diabetes mellitus. Autoimmunity 11: 53–59PubMedCrossRefGoogle Scholar
  99. Virtanen S.M., Saukkonen T., Savilahti E. et al. (1994) Diet, cow’s milk protein antibodies and the risk of IDDM in Finnish children. Childhood Diabetes in Finland Study Group. Diabetologia 37: 381–387PubMedCrossRefGoogle Scholar
  100. WHO (1985) Diabetes mellitus. Report of WHO Study Group. WHO Techn Rep Ser. WHO. 727Google Scholar
  101. WHO (1980) Expert Committee on Diabetes Mellitus. Second report. Technical report series. Geneva, WHOGoogle Scholar
  102. Wiley J. (1997) Genetics of Diabetes. In: Scheuner M.T., Raffel L.I., Rotter J.I., Alberti K.G.M.M., Zimmet P., De Fronzo R.A., Keen H. (eds) International Textbook of Diabetes mellitus. Chichester, pp 37–88Google Scholar
  103. Yang X., Michie S.A., Mebius R.E., Tisch R., Weissman I., McDevitt H.O. (1996) The Role of Cell Adhesion Molecules in the Development of IDDM. Implications for Pathogenesis and Therapy. Diabetes 45: 705–710PubMedCrossRefGoogle Scholar
  104. Yilmaz M.T., Devrim A.S., Biyal F. et al. (1993) Immunoprotection in spontaneous remission of type 1 diabetes: longterm follow-up results. Diabetes Res Clin Pract 19: 151–162PubMedCrossRefGoogle Scholar
  105. Zhang Z.I., Davidson L., Eisenbarth G., Weiner H.L. (1991) Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 88: 10252–10256PubMedCrossRefGoogle Scholar
  106. Ziegler A.G., Bachmann W., Rabl W. (1993) Prophylactic insulin treatment in relatives at high risk for type 1 diabetes. Diabetes Metab Rev 9: 289–293PubMedCrossRefGoogle Scholar
  107. Zimmet P. (1982) Type II (non-insulin dependent) diabetes-an epidemiological overview. Diabetologia 22: 399–411PubMedCrossRefGoogle Scholar
  108. Zumbach M., Butz B., Liedvogel B. et al. (1996) GAD-Antikiirper zur Diagnose eines Typ-1-Diabetes bei Patienten mit spater Manifestation. Diab Stoffw 5: 153–156Google Scholar

Literatur zu Abschn. 16.6

  1. Aguilar-Bryan L., Nichols C.G., Wechsler S.W. et al. (1995) Cloning of the β;-cell high-affinity sulfonylurea receptor: A regulator of insulin secretion. Science 268: 423–426PubMedCrossRefGoogle Scholar
  2. Araki E., Lipes M.A., Patti M.E., Bruning J.C., Haag B. rd, Johnson R.S., Kahn C.R. (1994) Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372: 186–190PubMedCrossRefGoogle Scholar
  3. Baier L.I., Saccettini J.C., Knowler W.C. et al. (1995) An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 95: 1281PubMedCrossRefGoogle Scholar
  4. Blankenhorn D.H., Azen S.P., Kramsch D.M. et al. (1993) Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 119: 969–976PubMedCrossRefGoogle Scholar
  5. Boden G., Chen X., Kolaczynski J.W., Polansky M. (1997) Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. J Clin Invest 100: 1107–1113PubMedCrossRefGoogle Scholar
  6. Burant C.F., Sreenan S., Hirano K.I. et al. (1997) Troglitazone action is independent of adipose tissue. J Clin Invest 100: 2900–2908PubMedCrossRefGoogle Scholar
  7. Chen N.G., Swick A.G., Romsos D.R. (1997) Leptin constrains acetylcholine-induced insulin secretion from pancreatic islets of ob/ob mice. J Clin Invest 100: 1174–1179PubMedCrossRefGoogle Scholar
  8. Colditz G.A., Willett W.C., Stampfer M.I., Manson J.E., Hennekens C.H., Arky R.A., Speizer F.E. (1990) Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 132: 301–513Google Scholar
  9. Coniff R.F., Shapiro J.A., Seaton T.B., Bray G.A. (1995) Multicenter, placebo-controlled trial comparing acarbose (BAY g5421) with placebo, tolbutamide, and tolbutamide-plus Acarbose in non-insulin-dependent diabetes mellitus. Am J Med 98: 443–451PubMedCrossRefGoogle Scholar
  10. DeFronzo R.A., Goodman A.M., and the Multicenter Metformin Study Group (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333: 541–549PubMedCrossRefGoogle Scholar
  11. De Koning E.J.P., Morris E.R., Hofhuis F.M.A. et al. (1994) Intra and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human amyloid polypeptide. Proc Natl Acad Sci USA 91: 8467–8471PubMedCrossRefGoogle Scholar
  12. Eastman R.C., Carson R.E., Gordon M.R. et al. (1990) Brain Glukose metabolism in non-insulin-dependent diabetes mellitus: a study in Pima Indians using positron emission tomography during hyperinsulinemia with euglycemic clamp. J Clin Endocrinol Metab 71: 1602–1610PubMedCrossRefGoogle Scholar
  13. Ericsson C.G., Hamsten A., Nilsson I., Grip L., Svane B., de Faire U. (1996) Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347: 849–853PubMedCrossRefGoogle Scholar
  14. Ferrannini E., Natali A., Bell P., Cavallo-Perin P., Lalic N., Mingrone G. (1997) Insulin resistance and hypersecretion in obesity. J Clin Invest 100: 1166–1173PubMedCrossRefGoogle Scholar
  15. Grant P.J., Strickland M.H., Mansfield M.W. (1995) Insulin receptor substrate-1 gene and cardiovascular risk factors in NIDDM [Letter]. Lancet 346: 841–842PubMedCrossRefGoogle Scholar
  16. Guillam M.T., Hümmler E., Schaerer E. et al. (1997) Early diabetes and abnormal postnatal pancreatic islet development in mice ladung Glut-2. Nature Genet 17: 327–330PubMedCrossRefGoogle Scholar
  17. Hager J., Hansen L., Vaisse C. et al. (1995) Amissense mutation in the Glukagon receptor gene is associated with non-insulin-dependent diabetes mellitus. Nature Genet 9: 299–304PubMedCrossRefGoogle Scholar
  18. Horikawa Y., Iwasaki N., Hara M. et al. (1997) Mutation in hepatocyte nudear factor-1β gene (TCF2) associated with MODY. Nature Genet 17: 384–385PubMedCrossRefGoogle Scholar
  19. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., Spiegelman B.M. (1996) IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesityinduced insulin resistance. Science 271: 665–668PubMedCrossRefGoogle Scholar
  20. Jonas M., Reicher-Reiss H., Boyko V., Shotan A., Mandelzweig L., Goldbourt U., Behar S. (1996) Usefulness of β;-blocker therapy in patients with non-insulin dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol 77: 1273–1277PubMedCrossRefGoogle Scholar
  21. Kahn S.E., Leonetti D.L., Prigeon R.L., Boyko E.I., Bergstom R.W., Fujimoto W.Y. (1996) Pro insulin levels predict the development of non-insulin-dependent diabetes mellitus (NIDDM) in Japanese-American men. Diabet Med 13 (Suppl): S63–S66PubMedGoogle Scholar
  22. Kelleher C., Kingston S.M., Barry D.G., Cole M.M., Ferriss J.B., Grealy G., Joyce C, O’Sullivan D.J. (1988) Hypertension in diabetic dinics patients and their siblings. Diabetologia 31: 76–81PubMedCrossRefGoogle Scholar
  23. Kirchgessner T.G., Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. (1997) Tumor necrosis factor a contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest 100: 2777–2782PubMedCrossRefGoogle Scholar
  24. Kulkarni R.N., Wang Z.L., Wang R.M. et al. (1997) Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest 100: 2729–2736PubMedCrossRefGoogle Scholar
  25. Leahy J.L. (1990) Natural history of β;-cell dysfunction in NIDDM. Diabetes Care 13: 992–1010PubMedCrossRefGoogle Scholar
  26. Maddux B.A., Sbraccia P., Kumakura S. et al. (1995) Membrane glycoprotein PC-1 and insulin resistance in non-insulindependent diabetes mellitus. Nature 373: 448–451PubMedCrossRefGoogle Scholar
  27. Maheux P., Azhar S., Kern P.A., Chen Y.D.I., Reaven G.M. (1997) Relationship between insulin-mediated Glukose disposal and regulation of plasma and adipose tissue lipoprotein lipase. Diabetologia 40: 850–858PubMedCrossRefGoogle Scholar
  28. McCance D.R., Pettitt D.J., Hanson R.L., Jacobsson L.T., Knowler W.C., Bennett P.H. (1994) Birth weight and non-insulin-dependent diabetes: thrifty genotype, thrifty phenotype, or surviving small baby genotype? BMJ 308: 942–945PubMedCrossRefGoogle Scholar
  29. Mueckler M., Kruse M., Strube M. et al. (1994) A mutation of the GLUT2 Glukose transporter gene of a diabetic patient abolishes transport activity. J Biol Chem 37: 17765Google Scholar
  30. Muller H.K., Kellerer M., Ermel B., Muhlhofer A., Obermaier-Kusser B., Vogt B., Haring H.U. (1991) Prevention by protein kinase C inhibitors of Glukose-induced insulin receptor tyrosine kinase resistance in rat fat cells. Diabetes 40: 1440–1448PubMedCrossRefGoogle Scholar
  31. Naggert J.K., Fricker L.D., Varlamov O. et al. (1995) Hyperpro-insulinaemia in obese fat/fat mice associated with a carboxypeptidase Emutation which reduces enzyme activity. Nature Genet 10: 135PubMedCrossRefGoogle Scholar
  32. National High Blood Pressure Education Program Working Group Report on Hypertension in Diabetes. (1994) Hypertension 23: 145–158CrossRefGoogle Scholar
  33. Olansky L., Janssen R., Welling C. et al. (1992) Variability ofthe insulin gene in American blacks with NIDDM. J Clin Invest 89: 1596PubMedCrossRefGoogle Scholar
  34. Pettitt D.J., Forman M.R., Hanson R.L., Knowler W.C., Bennett P.H. (1997) Breastfeeding and incidence of non-insulin-dependent diabetes mellitus in Pima Indians. Lancet 350: 166–168PubMedCrossRefGoogle Scholar
  35. Reynet C., Kahn C.R. (1993) Rad: A member of the ras family overexpressed in musde of Type II diabetic humans. Science 262: 1441–1444PubMedCrossRefGoogle Scholar
  36. Ricote M., Li A.C., Wilson T.M., Kelly C.J., Glass C.K. (1998) The peroxisome proliferator-activated receptor-y is a negative regulator of macrophage activation. Nature 391: 79–82PubMedCrossRefGoogle Scholar
  37. Roden M., Price T.B., Perseghin G., Peterson K.F., Rothman D.L., Cline G.W., Shulman G.I. (1996) Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97: 2859–2865PubMedCrossRefGoogle Scholar
  38. Saghizadeh M., Ong J.M., Garvey W.T., Henry R.R., Kern P.A. (1996) The expression of TNF-α1 by human muscle. J Clin Invest 97: 1111–1116PubMedCrossRefGoogle Scholar
  39. Scrocchi L.A., Brown T.I., Madusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., Drucker D.J. (1996) Glukose intolerance but normal satiety in mice with a null mutation in the Glukagon-like peptide 1 receptor gene. Nature Med 2: 1254–1258PubMedCrossRefGoogle Scholar
  40. Stenbit A.E., Tsao T.S., Li J. et al. (1997) GLUT4 heterozygous knockout mice develop musde insulin resistance and diabetes. Nature Med 3: 1096–1101PubMedCrossRefGoogle Scholar
  41. Stumvoll M., Nurjhan N., Perriello G., Dailey G., Gerich J.E. (1995) Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333: 550–554PubMedCrossRefGoogle Scholar
  42. Tamemoto H., Kadowaki T., Tobe K. et al. (1994) Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372: 182–186PubMedCrossRefGoogle Scholar
  43. Tenkanen L., Mänttäri M., Manninen V. (1995) Some coronary risk factors related to the insulin resistance sydrome and treatment with gemfibrozil. Circulation 92: 1779–1785PubMedCrossRefGoogle Scholar
  44. Turner R., Stratton I., Horton V. et al. (1997) UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350: 1288–1293PubMedCrossRefGoogle Scholar
  45. Von-Ferber L., Salzsieder E., Hauner H. et al. (1993) Diabetes prevalence from health insurance data: evaluation of estimates by comparison with a population-based diabetes register. Diabetes Met 19: 89–95Google Scholar
  46. Wachtel T.H., Silliman R.A., Lamberton P. (1987) Predisposing factors for the diabetic hyperosmolar state. Arch Intern Med 147: 499–501PubMedCrossRefGoogle Scholar
  47. Walston J., Silver K., Bogardus C. et al. (1995) Earlier onset of non-insulin-dependent diabetes mellitus in subjects with a mutation in the β3-adrenergic receptor gene. N Engl J Med 333: 337CrossRefGoogle Scholar
  48. Wu Z., Xie Y., Morrison R.F., Bucher N.L.R., Farmer S.R. (1998) PPAR induces the insulin-dependent Glukose transporter GLVT4 in the absence of C/EBP α during the conversion of 3T3 fibroblasts into adipocytes. J Clin Invest 101: 22–32PubMedCrossRefGoogle Scholar
  49. Yamagata K., Oda N., Kaisaki P.J. et al. (1996) Mutations in the hepatocyte nuclear factor-1α in maturity-onset diabetes of the young (MODY3). Nature 384: 455–458PubMedCrossRefGoogle Scholar
  50. Yamagata K., Furuta H., Oda N. et al. (1996) Mutations in the hepatocyte nuclear factor-4α gene in maturity-onset diabetes of the young (MODY1). Nature 384: 458–460Google Scholar
  51. Yki-Jarvinen H., Kauppila M., Kujansuu E. et al. (1992) Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327: 1426PubMedCrossRefGoogle Scholar
  52. Zawalich W.S., Kelley G.G. (195) The pathogenesis of NIDDM: the role of the pancreatic beta cell. Diabetologia 38: 986–999CrossRefGoogle Scholar
  53. Zhang Y., Wat N., Stratton I.M., Warren-Perry M.G., Orho M., Groop L., Turner R.C. (1996) VKPDS 19: Heterogeneity in NIDD~: separate contributions of IRS-1 and β3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations. Diabetolgia 39: 1503–1511.CrossRefGoogle Scholar

Literatur zu Abschn. 16.7

  1. Dornhorst A., Girling J.C. (1995) Management of gestational diabetes mellitus. N Engl J Med 333: 1281–1282PubMedCrossRefGoogle Scholar
  2. Eriksson V., Dahlström E., Larsson K.S., Hellerström C. (1982) Increased incidence of congenital malformations in the offspring of diabetic rats and their prevention by maternal insulin therapy. Diabetes 31: 1–6Google Scholar
  3. Fritsche A., Schmülling R. (1995) Gestationsdiabetes wird häufig zu spät erkannt. Forschung und Praxis 200: 19–22Google Scholar
  4. Hillebrand B. (1996) Schwangerschaft und Diabetes. Ernährungsumschau 43: 40–43Google Scholar
  5. Jang H.C., Cho N.H., Min Y-K., Han I.K., Jung K.B., Metzger B.E. (1997) Increased macrosomia and perinatal morbidity independent of maternal obesity and advanced age in korean women with GDM. Diabetes Care 20: 1582–1588PubMedCrossRefGoogle Scholar
  6. Kuruvilla A.G., D’Souza S.W., Glazier J.D., Mahendran D., Maresh M.J., Sibley C.P. (1994) Altered activity of the system of amino acid transporter in microvillous membrane vesicles from placentas of macrosomic babies born to diabetic women. J Clin Invest 94: 689–695 Lea R.G., McCracken J.E., McIntyre S.S., Smith W., Baird J.D. (1996) Disturbed development ofthe preimplantation embryo in the insulin-dependent diabetic BB/E rat. Diabetes 45: 1463–1470PubMedCrossRefGoogle Scholar
  7. Mackie A.D.R., Doddridge M.C., Gamsu H.R., Brudenell J.D., Nicolaides K.H., Drury P.L. (1996) Outcome of pregnancy in patients with insulin-dependent diabetes mellitus and nephropathy with moderate renal impairment. Diabetic Medicine 13: 90–96PubMedCrossRefGoogle Scholar
  8. Müller V.A., Hunger-Dathe W., Kobes M., Reuber E., Kirchner D. (1995) Qualität der Stoffwechseleinstellung bei Typ-1-Diabetikern ein Jahr nach Teilnahme an einem strukturierten Behandlungsprogramm für intensivierte konventionelle Insulintherapie. Diabet Stoffw 4: 9–13Google Scholar
  9. Page R.C.L., Kirk B.A., Fay T., Wilcox M., Hosking D.J., Jeffcoate W.J. (1995) Is macrosomia associated with poor glycaemic control in diabetic pregnancy. Diabetic Medicine 13: 170–174CrossRefGoogle Scholar
  10. Phelan S.A., Ito M., Loeken M.R. (1997) Neural tube defects in embryos of diabetic mice. Diabetes 46: 1189–1197PubMedCrossRefGoogle Scholar
  11. Piacquadio K., Hollingsworth D.R., Murphy H. (1991) Effects of in-utero exposure to oral hypoglycaemic drugs. Lancet 338: 866–869PubMedCrossRefGoogle Scholar
  12. Reece E.A., Eriksson V.J. (1996) The pathogenesis of diabetes-associated congenital malformations. Obstetrics and gynecology clinics of north america 23: 29–45PubMedCrossRefGoogle Scholar
  13. Siman C.M., Eriksson U.J. (1997) Vitamin E decreases the occurrence of malformations in the offspring of diabetic rats. Diabetes 46: 1054–1061PubMedCrossRefGoogle Scholar
  14. Simmons D., Robertson S. (1997) Influence of maternal insulin treatment on the infants of women with gestational diabetes. Diabetic Medicine 14: 762–765PubMedCrossRefGoogle Scholar
  15. Steinhart J.R., Sugarman J.R., Connell F.A. (1997) Gestational diabetes is a herald of NIDDM in navajo women. Diabetes Care 20: 943–947PubMedCrossRefGoogle Scholar
  16. Veciana de M., Major C.A., Morgan M.A., Asrat T., Toohey J.S., Lien J.M., Evans A.T. (1995) Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 333: 1237–1241PubMedCrossRefGoogle Scholar
  17. Vohr B.R., McGarvey S.T. (1997) Growth patterns of large-forgestational-age and appropriate-for-gestational-age infants of gestational diabetic mothers and control mothers at age 1 year. Diabetes Care 20: 1066–1072PubMedCrossRefGoogle Scholar

Literatur zu Abschn. 16.8

  1. Beischer N.A., Oats J.N., Henry O.A., Sheedy M.T., Walstab J.E. (1991) Incidence and severity of gestational diabetes melitus according to country ofbirth in women living in australia. Diabetes 40(Suppl. 2): 35–38PubMedGoogle Scholar
  2. Dornhorst A., Girling J.C. (1995) Management of gestational diabetes mellitus. N Engl J Med 19: 1281–1282CrossRefGoogle Scholar
  3. Festa A., Schernthaner G. (1995) Klinische Relevanz des Gestationsdiabetes. Pathophysiologie, Epidemiologic, Screening, Diagnose und Therapie. Diabetes Stoffw 4: 21–29Google Scholar
  4. Fritsche A., Schmülling R. (1995) Gestationsdiabetes wird häufig zu spät erkannt. Forschung und Praxis 200: 19–22Google Scholar
  5. Greene M.F. (1997) Screening for gestational diabetes mellitus. N Engl J Med 22: 1625–1626CrossRefGoogle Scholar
  6. Hadden D.R. (1985) Geographic, ethnic and racial variations in the incidence of gestational diabetes mellitus. Diabetes 34 (Suppl. 2): 8–12PubMedGoogle Scholar
  7. Hillebrand B. (1996) Schwangerschaft und Diabetes. Ernährungsumschau 43: 40–43Google Scholar
  8. Jang H.C., Cho N.H., Min Y.K., Jung K.B., Metzger B.E. (1997) Increased macrosomia and perinatal morbidity independent of matern al obesity and advanced age in korean women with GDM. Diabetes Care (vol. 20) 10: 1582–1588PubMedCrossRefGoogle Scholar
  9. Nahum G.G., Huffaker B.J. (1993) Racial differences in oral glucose screening test results: Establishing race-specific criteria for abnormality in pregnancy. Obstet Gynecol 81: 517–522PubMedGoogle Scholar
  10. Naylor C.D., Sermer M., Chen E., Farine D. (1997) Selective screening for gestational diabetes mellitus. N Engl J Med 22: 1591–1596CrossRefGoogle Scholar
  11. Page R.C.L., Kirk B.A., Fay T., Wilcox M., Hosking D.J., Jeffcoate W.J. (1996) Is macrosomia associated with poor glycaemic control in diabetic pregnancy. Diabet Med 13: 170–174PubMedCrossRefGoogle Scholar
  12. Piacquadio K., Hollingsworth D.R., Murphy H. (1991) Effects of in-utero exposure to oral hypoglylcaemic drugs. Lancet 338: 866–869PubMedCrossRefGoogle Scholar
  13. Simmons D., Robertson S. (1997) Influence of maternal insulin treatment on the infants of women with gestational diabetes. Diabet Med 14: 762–765PubMedCrossRefGoogle Scholar
  14. Steinhardt J.R., Sugarman J.R., Connell F.A. (1997) Gestational diabetes is a herald of NIDDM in Navajo women. High rate of abnormal glucose tolerance after GDM. Diabetes Care (vol. 20) 6: 943–947CrossRefGoogle Scholar
  15. The expert committee on the diagnosis and classification of diabetes mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care (vol. 20) 1183–1197Google Scholar
  16. de Veciana M., Major C.A., Morgan M.A., Asrat T., Toohey J.S., Lien J.M., Evans A.T. (1995) Postprandial versus preprandial blood glukose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 19: 1237–1241CrossRefGoogle Scholar
  17. Vohr B.R., McGarvey S.T. (1997) Growth patterns of large-forgestational-age and appropriate-for-gestational-age infants of gestational diabetic mothers and control mothers at age 1 year. Diabetes Care (vol. 20) 7: 1066–1072PubMedCrossRefGoogle Scholar

Literatur zu Abschn. 16.9

  1. Amiel S.A. (1997) Hypoglycaemia in diabetes mellitus-protecting the brain. Diabetologia 40(Suppl. 2): S62–S68PubMedCrossRefGoogle Scholar
  2. Biessels G.J., Kappelle A.C., Bravenboer B., Erkelens D.W., Gispen W.H. (1994) Cerebral function in diabetes mellitus. Diabetologia 37(7): 643–650PubMedCrossRefGoogle Scholar
  3. Biggers D.W., Myers S.R., Neal D. et al. (1989) Role of brain in counterregulation of insulin-induced hypoglycemia in dogs. Diabetes 38(1): 7–16PubMedCrossRefGoogle Scholar
  4. Blackman J.D., Towle V.L., Sturis J., Lewis G.F., Spire J.P., Polonsky K.S. (1992) Hypoglycemie thresholds for cognitive dysfunction in IDDM. Diabetes 41(3): 392–399PubMedCrossRefGoogle Scholar
  5. Bode B.W., Steed R.D., Davidson P.C. (1996) Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care 19(4): 324–327PubMedCrossRefGoogle Scholar
  6. Boyle P.J. (1997) Alteration in brain glucose metabolism induced by hypoglycaemia in man. Diabetologia 40(Suppl. 2): S69–S74PubMedCrossRefGoogle Scholar
  7. Brunelle B.L., Llewelyn J., Anderson J.H. Jr, Gale E.A., Koivisto V.A. (1998) Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 21(10): 1726–1731Google Scholar
  8. Cersosimo E., Molina P.E., Abumrad N.N. (1997) Renal glucose production during insulin-induced hypoglycemia. Diabetes 46(4): 643–646PubMedCrossRefGoogle Scholar
  9. Chalew S.A., Mersey J.H., Kowarski A.A. (1990) Evidence for elevated glucose threshold in patients with impaired glucose tolerance and symptoms of hypoglycemia during OGTT. Diabetes Care 13(5): 507–512PubMedCrossRefGoogle Scholar
  10. Clutter W.E., Rizza R.A., Gerich J.E., Cryer P.E. (1988) Regulation of glucose metabolism by sympathochromaffin catecholamines. Diabetes Metab Rev 4(1): 1–15PubMedCrossRefGoogle Scholar
  11. De Feo P., Perriello G., Torlone E. et al. (1989) Contribution of cortisol to glucose counterregulation in humans. Am J Physiol 257(1 Pt 1): E35–E42PubMedGoogle Scholar
  12. Debrah K., Sherwin R.S., Murphy J., Kerr D. (1996) Effect of caffeine on recognition of and physiological responses to hypoglycaemia in insulin-dependent diabetes. Lancet 347(8993): 19–24PubMedCrossRefGoogle Scholar
  13. Gold A.E., Deary I.J., Frier B.M. (1997) Hypoglycaemia and noncognitive aspects of psychological function in insulin-dependent (type 1) diabetes mellitus (IDDM). Diabet Med 14(2): 111–118PubMedCrossRefGoogle Scholar
  14. Gomez B., Garcia-Villallon A.L., Frank A., Garcia J.L., Monge L., Dieguez G. (1992) Effects ofhypoglycemia on the cerebral circulation in awake goats. Neurology 42(4): 909–916PubMedCrossRefGoogle Scholar
  15. Hepburn D.A., MacLeod K.M., Pell A.C., Scougal I.J., Frier B.M. (1993) Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med 10(3): 231–237PubMedCrossRefGoogle Scholar
  16. Herings R.M., de Boer A., Stricker B.H., Leufkens H.G., Porsius A. (1995) Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 345(8959): 1195–1198PubMedCrossRefGoogle Scholar
  17. Holleman F., Hoekstra J.B. (1997) Insulin lispro. N Engl J Med 337(3): 176–183PubMedCrossRefGoogle Scholar
  18. Klein B.E., Klein R., Moss S.E. (1997) Risk of hypoglycemia in users of human insulin. The Wisconsin Epidemiologic study of Diabetic Retinopathy. Diabetes Care 20(3): 336–339PubMedCrossRefGoogle Scholar
  19. Kolaczynski J.W., Ylikahri R., Harkonen M., Koivisto V.A. (1988) The aeute effect of ethanol on counterregulatory response and recovery from insulin-induced hypoglycemia. J Clin Endocrinol Metab 67(2): 38438–8CrossRefGoogle Scholar
  20. Lecavalier L., Bolli G., Cryer P., Gerich J. (1989) Contributions of gluconeogenesis and glycogenolysis during glucose counterregulation in normal humans. Am J Physiol 256(6 Pt 1): E844–851Google Scholar

Literatur zu Abschn. 16.10

  1. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J. (1996) Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet 347(9004): 781–786PubMedCrossRefGoogle Scholar
  2. Yokoyama I., Ohtake T., Momomura S. et al. (1998) Hyperglycemia rather than insulin resistance is related to reduce coronary flow reserve in NIDDM. Diabetes 47(1): 119–124PubMedCrossRefGoogle Scholar
  3. Abraira C., Colwell J., Nuttal F. et al. (1997) Cardiovascular event and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 152(2): 181–188CrossRefGoogle Scholar
  4. Airaksinen K.E., Koistinen M.J. (1992) Association between silent coronary artery disease, diabetes, and autonomic neuropathy. Fact or fallacy? Diabetes Care 15(2): 288–292PubMedGoogle Scholar
  5. Ambipityia G., Kopelman P.G., Ingram D., Swash M., Mills P.G., Timmis A.D. (1990) Exertional myocardial ischemia in diabetes: a quantitative analysis of anginal perceptual threshold and the influence of autonomic function. J Am Coll Cardiol 15(1): 72–77CrossRefGoogle Scholar
  6. Aronson C., Bloomgarden Z., Rayfiled E.J. (1996) Potential mechanisms promoting re stenosis in diabetic patients. J Am Coll Cardiol 1996, 27(3): 528–535CrossRefGoogle Scholar
  7. Assmann G., Schulte H. (1989) Diabetes mellitus and hypertension in the elderly: concomitant hyperlipidemia and coronary heart disease risk. Am J Cardiol 63(16): 33H-37HGoogle Scholar
  8. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic (CARPIE). Lancet 348(9038): 1329–1339CrossRefGoogle Scholar
  9. Carmeliet P., Moons L., Lihnen R., Janssens S., Lupu F., Collen D., Gerard R.D. (1997) Inhibitory role of plasminogen activator inhibitor-l in arterial wound healing and neo intima formation: a gene targeting and gene transfer study in mice. Circulation 96(9): 180–191CrossRefGoogle Scholar
  10. Ceriello A. (1993) Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. 36(11): 1119–1125Google Scholar
  11. Ceriello A., Giugliano D., Quatraro A., Marchi F., Barbanti M., Lefebvre P. (1990) Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans. Diabetologia 33(3): 163–167PubMedCrossRefGoogle Scholar
  12. Chun B.Y., Dobson A.J., Heller R.F. (1997) The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care 20(5): 704–708PubMedCrossRefGoogle Scholar
  13. Clarkson P., Celermajer D.S., Donald A.E. et al. (1996) Impaired vascular reactivity in insulin-depended diabetes mellitus is related to disease duration and low density lipoprotein cholesterollevels. J Am Coll Cardiol 28(3): 573–579PubMedCrossRefGoogle Scholar
  14. Davi G., Catalano I., Averna M., Notarbartolo A., Strano A., Ciabattoni G., Patrono C. (1990) Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322(25): 1769–1774PubMedCrossRefGoogle Scholar
  15. Elezi S., Kastrati A., Pache J. et al. (1998) Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 32(7): 1866–1873PubMedCrossRefGoogle Scholar
  16. Fava S., Azzopardi J., Agius-Muscat H. (1997) Outcome of unstable angina in patients with diabetes mellitus. Diabet Med 14(3): 209–213PubMedCrossRefGoogle Scholar
  17. Foley R.N., Culleton B.F., Parfrey P.S., Harnett J.C., Kent G.M., Murray D.C., Barre P.E. (1997) Cardiac disease in diabetic endstage renal disease. Diabetologia 40(11): 1307–1312PubMedCrossRefGoogle Scholar
  18. Giugliano D., Marfella R., Verrazzo G. et al. (1995) Abnormal rheologic effects of glyceryl trinitrate in patients with non-insulin-dependent diabetes mellitus and revers al by antioxidants. Ann Intern Med 123(4): 338–343PubMedCrossRefGoogle Scholar
  19. Goldberg R.B., Mellies M.I., Sacks F.M. et al. (1998) Cardiovascular events and their reduction with Pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Circulation 98(23): 2513–2519PubMedCrossRefGoogle Scholar
  20. Granger C.B., Aronson L., Wall T.C. (1993) The impact of diabetes on survival in acute myocardial infarction: the TAMI experience. J Am Coll Cardiol 14(Suppl. A): 198AGoogle Scholar
  21. Granger C.B., Califf R.M., Young S. et al. (1993) Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 21(4): 920–905PubMedCrossRefGoogle Scholar
  22. Gray R.P., Yudkin J.S., Patterson D.L. (1993) Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br Heart J 70(6): 530–536PubMedCrossRefGoogle Scholar
  23. Grossman E., Messerli F.H. (1996) Diabetic and hypertensive he art disease. Ann Intern Med 125(4): 304–310PubMedCrossRefGoogle Scholar
  24. Guigliano D., Ceriello A., Paoliso G. (1995) Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress? Metabolism 44(3): 363–368CrossRefGoogle Scholar
  25. Hasenfuss G. (1995) Cardiac changes in diabetes. Exp Clin Endocrinol Diabetes 103(6): 352–353PubMedCrossRefGoogle Scholar
  26. Herlitz I., Wognsen G.B., Emanuelsson H. et al. (1996) Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care 19(7): 698–703PubMedCrossRefGoogle Scholar
  27. Hlatky M.A., Rogers W.I., Johnstone I. et al. (1997) Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 336(2): 92–99PubMedCrossRefGoogle Scholar
  28. Hofmann M.A., Kohl B., Zumbach M.S. et al. (1998) Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 21(5): 841–848PubMedCrossRefGoogle Scholar
  29. Jacoby R.M., Nesto R.W. (1992) Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol 20(3):736–744PubMedCrossRefGoogle Scholar
  30. Jank H.W.: Diabetes Stoffw 5: 24–28Google Scholar
  31. Jensen-Urstad K.I., Reichard P.G., Rosfors J.S., Lindblad L.E., Jensen-Urstad M.T. (1996) Early atherolsclerosis is retarded by improved blood glucose control in patients with IDDM. Diabetes 45(9): 1253–1258PubMedCrossRefGoogle Scholar
  32. Jonas M., Reicher-Reiss I.I., Boyko V., Shotan A., Manderlzweig L., Goldbourt U., Behar S. (1996) Usefulness of (J-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infaretion Prevention (EIP) Study Group. Am J Cardiol 77(15): 1273–1277PubMedCrossRefGoogle Scholar
  33. Kaplan N.M. (1989) The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149(7): 1514–1520PubMedCrossRefGoogle Scholar
  34. Kjekshus I., Gilpin E., Cali G., Blackey A.R., Henning H., Ross J. Jr (1990) Diabetic patients and β-blockers after acute myocardial infarction. Eur Heart J 11(1): 43–50PubMedGoogle Scholar
  35. Kleiman N.S., Lincoff A.M., Kereiakes D.J. et al. (1998) Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation 19,97(19): 1912–1920CrossRefGoogle Scholar
  36. Kluijtmans L.A., van den Heuvel L.P., Boers G.H. et al. (1996) Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 58(1): 35–41PubMedGoogle Scholar
  37. Kornowski R., Mintz G.S., Kent K.M. et al. (1997) Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated hyperplasia. A scribal intravascular ultra sound study. Circulation 95(6): 1366–1369PubMedCrossRefGoogle Scholar
  38. Kuusisto J., Mykkanen L., Pyorala K., Laakso M. (1994) NIDDM and its metabolic control predict coronary he art disease in elderly subjects. Diabetes 43(8): 960–967PubMedCrossRefGoogle Scholar
  39. Lamarche B., Tchernof A., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Despres J.P. (1997) Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95(1): 69–75PubMedCrossRefGoogle Scholar
  40. Lehmann E.D., Riley W.A., Clarkson P., Gosling R.G. (1997) Noninvasive assessment of cardiovascular disease in diabetes mellitus. Lancet 350(Suppl. I): S114–S119Google Scholar
  41. Lopes-Virella M.F., Virella G. (1996) Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes 45(Suppl. 3): S40–S44PubMedGoogle Scholar
  42. Lynch M., Garnrnage M.D., Lamb P., Nattrass M., Pentecost B.L. (1994) Acute myocardial infarction in diabetic patients in the thrombolytic era. Diabet Med 11(2): 162–165PubMedCrossRefGoogle Scholar
  43. Mattock M.B., Barnes D.I., Viberti G. et al. (1998) Microalbuminuria and coronary heart disease in NIDDM: an incidence study. Diabetes 47(11): 1786–1792PubMedCrossRefGoogle Scholar
  44. Moncada S., Higgs A. (1993) The L-arginine-nitric oxide pathway. N Engl J Med 329(27): 2002–2012PubMedCrossRefGoogle Scholar
  45. Mueller H.S., Cohen L.S., Braunwald E. et al. (1992) Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patients subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Circulation 85(4): 1254–1264CrossRefGoogle Scholar
  46. Murray D.P., O’Brien T., Mulrooney R., O’Sullivan D.J. (1990) Autonomic dysfunction and silent myocardial ischemia on exercise testing in diabetes mellitus. Diabet Med 7(7): 580–584PubMedCrossRefGoogle Scholar
  47. Oliver M.F., Opie L.H. (1994) Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 343(8890):155–158PubMedCrossRefGoogle Scholar
  48. Orth S.R., Ritz E., Schrier R.W. (1997) The renal risks of smoking. Kidney Int 51(6): 1669–1677PubMedCrossRefGoogle Scholar
  49. Paolisso G., Gambardalla A., Giugliano D. et al. (1995) Chronic intake of pharmacological doses of vitamin E might be useful in the therapy of elderly patients with coronary heart disease. Am J Clin Nutr 61(4):848–852PubMedGoogle Scholar
  50. Psaty B.M., Heckbert S.R., Koepsell T.D. et al. (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274(8): 620–625PubMedCrossRefGoogle Scholar
  51. Pyörälä K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., Thorgeirsson G. (1997) Cholesterollowering with simvastatin improves prognosis of diabetic patients with coronary he art disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20(4): 614–620PubMedCrossRefGoogle Scholar
  52. Riggs T.W., Transue D. (1990) Doppler echocardiographic evaluation ofleft ventricular diastolic function in adolescents with diabetes mellitus. Am J Cardiol 65(13): 899–902CrossRefGoogle Scholar
  53. Ryden Ahlgren A., Lanne T., Wollmer P., Sonesson B., Hansen F., Sundkvist G. (1995) Increased arte rial stiffness in women, but not in men with IDDM. Diabetologia 38(9): 1082–1089Google Scholar
  54. Sacks F.M., Pfeffer M.A., Moye L.A. et al. (1996) The effect of pravastatin on coronary events after myocardial infaretion in patients with average eholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335(14): 1001–1009PubMedCrossRefGoogle Scholar
  55. Savage M.P., Fisehman D.L., Slota P. el al. (1992) Association of HbAlc with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 42(2):202–208Google Scholar
  56. Stamler I., Vaccaro O., Neton J.D., Wentworth D. (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16(2): 434–444PubMedCrossRefGoogle Scholar
  57. Stein B., Weintraub W.S., Gebhart S.P. et al. (1995) Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 91(4):979–989PubMedCrossRefGoogle Scholar
  58. Syvänne M., Kahri I., Virtanen K.S., Taskinen M.R. (1995) HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus. Circulation 92(3):364–370PubMedCrossRefGoogle Scholar
  59. Taskinen M.R., Smith U. (1998) Lipid disorders in NIDDM: implications for treatment. J Intern Med 244(5): 361–370PubMedCrossRefGoogle Scholar
  60. Taylor G.J., Moses H.W., Katholi R.E. et al. (1992) Six-year survival after coronary thrombolysis and early revascularization for acute myocardial infarction. Am J Cardiol 79(1): 26–30CrossRefGoogle Scholar
  61. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Engl J Med 329(14): 977–986CrossRefGoogle Scholar
  62. Ting H.H., Timimi F.K., Boles K.S., Creager S.I., Ganz P., Creager M.A. (1996) Vitamin C improves endothelium-dependent vasodilatation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 97(1): 22–28PubMedCrossRefGoogle Scholar
  63. Topol E.J., Califf R.M., Weisman H.F. et al. (1994) Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 343(8902): 881–886PubMedCrossRefGoogle Scholar
  64. Tuomilehto I., Rastenyte D., Birkenhager W.H. et al. (1999) Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 4; 340(9): 677–684PubMedCrossRefGoogle Scholar
  65. Turner R., Cull C., Holman R. (1996) United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complication in non-insulin-dependent diabetes mellitus. Ann Intern Med 124(1 Pt 2): 136–1145PubMedCrossRefGoogle Scholar
  66. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 12; 317/7160): 703–713CrossRefGoogle Scholar
  67. UK Prospective Diabetes Study Group (UKPDS) (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352(9131):837–853CrossRefGoogle Scholar
  68. Zheng Z.J., Sharett A.R., Chambless I.E. et al. (1997) Association of angle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherolsclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 131(1): 115–125PubMedCrossRefGoogle Scholar

Literatur zu Abschn. 16.11

  1. Bierman E.L. (1992) George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb 12(6): 647–656PubMedCrossRefGoogle Scholar
  2. Bloomgarden Z.T. (1996) American Diabetes Association annual meeting 1996: the etiology of type II diabetes, obesity, and the treatment of type II diabetes. Diabetes Care 19(11): 1311–1315PubMedGoogle Scholar
  3. CAPRIE Steering Committee (1996) A ramdomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 16; 348(9038): 1329–1339CrossRefGoogle Scholar
  4. Currie C.I., Morgan C.L., Peters J.R. (1998) The epidemiology and cost of in patient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care 21(1): 42–48PubMedCrossRefGoogle Scholar
  5. Diehm C., Weiss T. (1997) PAVK Fibel. Lingua MedizinGoogle Scholar
  6. Faglia E., Favales F., Quarantiello A., Calia P., Brambilla G., Rampoldi A., Morabito A. (1996) Feasibility and effecttiveness of peripheral percutaneous transluminal balloon angioplasty in diabetic subjects with foot ulcers. Diabetes Care 19(11): 1261–1264PubMedCrossRefGoogle Scholar
  7. GISAP Study (1994) Evaluation of a conservative treatment with iloprost in severe peripheral occlusive arterial disease (POAD). GISAP Study. Int Angiol 13(1): 70–74Google Scholar
  8. Meigs J.B., Nathan D.M., Cuppies L.A., Wilson P.W., Singer D.E. (1996) Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. J Clin Epidemiol 49(4): 411–417PubMedCrossRefGoogle Scholar
  9. Orchard T.I., Dorman J.S., Maser R.E. et al. (1990) Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 39(9): 1116–1124PubMedCrossRefGoogle Scholar
  10. Patrono C., Davi G. (1993) Antiplatelet agents in the prevention of diabetic vascular complications, Diabetes Metab Rev 9(3): 177–188PubMedCrossRefGoogle Scholar
  11. Shepherd J.T. (1992) The evolving knowledge of the physiopathology of the circulation in the human limbs. From sympathectomy to molecular biology. Int Angiol 11(1): 8–13PubMedGoogle Scholar
  12. Singer D.E., Nathan D.M., Anderson K.M., Wolson P.W., Evans J.C. (1992) Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 41(2): 202–208PubMedCrossRefGoogle Scholar
  13. Standl E. (1996) Metabolic syndrome and fatal quartet, Internist 37(7): 698–704PubMedGoogle Scholar
  14. Standl E., Mendler G., Zimmermann R., Stiegler H. (1996) Zur Amputationshäufigkeit von Diabetikern in Deutschland. Diabetes Stoffw 5: 29–32Google Scholar
  15. Starringer G. (1996) Informationsbroschüre des Arbeitskreises pA VK: Schaufenster pA VK (1/96). ASMA Medien GmbHGoogle Scholar
  16. Stiegler H. (1996) Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i. v. ProstagIandin E1 bei Diabetikern mit AVK im Stadium IV, V ASA Supplementum 35 zum 21. Jahrestag der Deutschen Gesellschaft für AngiologieGoogle Scholar
  17. Stiegler H. (1996) Oral anticoagulation in activated protein C resistance? Dtsch Med Wochenschr 20; 121(51-52):1619PubMedGoogle Scholar
  18. Stiegler H., Standl E., Frank S., Mendler G. (1998) Failure of reducing lower extremity amputations in diabetic patients: result of two subsequent population based surveys 1990 and 1995 in Germany. Vasa 27(1): 10–14PubMedGoogle Scholar
  19. Wienert V. et al. (1995) Kagerer KommunikationGoogle Scholar

Literatur zu Abschn. 16.12

  1. Aiello L.P. (1997) Vascular endothelial growth factor. 20th-century mechanisms, 21st century therapy. Invest Ophthalmol Vis Sci 38: 1647–1652PubMedGoogle Scholar
  2. DCCT Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986CrossRefGoogle Scholar
  3. Hammes H.P. and Brownlee M. (1996) Advanced glycation endproducts and the pathogenesis of diabetic complications. In: Lereoith D.L., Olefsky J.M., Taylor S. (eds) Diabetes mellitus: A fundamental and clinical text. Lippincott, Philadelphia, pp 810–815Google Scholar
  4. Hollwich F. (1988) Augenheilkunde. Thieme, StuttgartGoogle Scholar
  5. Klein R., Klein B.E., Moss S.E. (1992) Epidemiology of proliferative diabetic retinopathy. Diabetes Care 15: 1875–1891PubMedCrossRefGoogle Scholar
  6. Klein R., Klein B.E.K., Moss S.E. et al. (1984) The Wisconsin epidemiologic study of diabetic retinopathy: 11. Prevalence and risk of diabetic retinopathy when the age at diagnosis is less than 30 years. Arch Ophthalmol 102: 520–526PubMedCrossRefGoogle Scholar
  7. Klein R., Klein B.E.K., Moss S.E. et al. (1984) The Wisconsin epidemiologic study of diabetic retinopathy: III. Prevalence and risk when the age at diagnosis is 30 or more years. Arch Ophthalmol 102: 527–32PubMedCrossRefGoogle Scholar
  8. Lemmen K.D. (1993) Stadien-Einteilung und Laser-Therapie für die nichtproliferative diabetische Retinopathie und die diabetische Makulopathie. Der Augenarzt 27: 70–78Google Scholar
  9. Pfeiffer A., Schatz H. (1995) Diabetic microvascular complications and growth factors. Exp Chn Endocrinol Diabetes 103:7–14CrossRefGoogle Scholar
  10. Trautner C. Icks A., Haastert B., Plum F., Berger M. (1997) Incidence ofblindness in relation to diabetes. A populationbased study. Diab Care 20: 1147–1153CrossRefGoogle Scholar
  11. Trautner C., Icks A., Haastert B., Plum F., Berger M. (1997) Incidence of blindness in relation to diabetes. A populationbase study. Diabetes Care 20: 1147–1153PubMedCrossRefGoogle Scholar

Literatur zu Abschn. 16.13

  1. Anderson P.W., Zhang X.Y., Tian J. et al. (1996) Insulin and angiotensin II are addditive in stimulating TGF ß1 and matrix mRNA’s in mesangial cells. Kidney Int 50: 745–753PubMedCrossRefGoogle Scholar
  2. Anderson S.S., Tsilibary E.C., Charonis A.S. (1993) Nonenzymatic glycosylation induced modifications of intact bovine kidney tubular basement membrane. J Clm Invest 6: 3045–3052CrossRefGoogle Scholar
  3. Bakris G.L., Copley J.B., Vieknair N., Sadler R., Leurfgans S. (1996) Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50(5): 1641–1650PubMedCrossRefGoogle Scholar
  4. Berg T.J., Bangstad H.J., Torjesen P.A., Osterby R., Bucala R., Hanssen K.F. (1997) Advanced glycation end products in serum predict ehanges in the kidney morphology of patients with insulin dependent diabetes mellitus. Metabolism 46(6): 661–665PubMedCrossRefGoogle Scholar
  5. Bierhaus A., Ritz E., Nawroth P.P. (1996) Expression of receptors for advanced glycation end products in oeclusive vascular and renal disease. Nephrol Dial Transplant 11(Suppl. 5): 87–90PubMedCrossRefGoogle Scholar
  6. Böhlen L., de Courten M., Weidmann P. (1994) Comparative study of the Effect of ACE Inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 7: 84S-92S.Google Scholar
  7. Breyer J.A., Bain R.P., Evans J.K. et al. (1996) Predictors of the progression of renal insufficiency in patients with insulin dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 50(5): 1651–1658PubMedCrossRefGoogle Scholar
  8. Bucala R., Makita Z., Vega G., Grundy S., Koschinsky T., Cerami A., Vlassara H. (1994) Modification oflow density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91(20): 9441–9445PubMedCrossRefGoogle Scholar
  9. Colwell J. (1996) Intensive insulin therapy in type II diabetes. Diabetes 45: 87–90Google Scholar
  10. Crepaldi G., Carta Q., Defferari G. et al. (1998) Effects of lisinopril and nifedipine on the progression to overt albummna in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 21(1): 104PubMedCrossRefGoogle Scholar
  11. de Gasparo M., Levens N. (1994) Pharmacology of angiotensin II receptors in the kidney. Kidney Int 46: 1486–1491PubMedCrossRefGoogle Scholar
  12. Elving L.D., Wetzels J.F., de Nobel E., Berden J.H. (1991) Erythroeyte sodium lithium countertransport is not different in type 1 (insulin dependent) diabetic patients with and wühout diabetic nephropathy. Diabetologia 34(2): 126–128PubMedCrossRefGoogle Scholar
  13. Elving L.D., Wetzels J.F., de Nobel E., Hoitsma A.J., Berden J.H. (1992) Captopril aeutely lowers albummuna m normotensive patients with diabetic nephropathy. Am J Kidney Dis 20(6): 559–563PubMedGoogle Scholar
  14. Gall M.A.; Nielsen F.S.; Smidt U.M.; Parving H.H. (1993) The course ofkidney function in type 2 (non insulin dependent) diabetic patients with diabetic nephropathy. Diabetologia. 36(10): 1071–1078PubMedCrossRefGoogle Scholar
  15. Gambaro G., Venturini A.P., Noonan D.M. et al. (1994) Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 46(3): 797–806PubMedCrossRefGoogle Scholar
  16. Geberth S., Lippert I., Ritz E. (1993) The apparent“ epidemic” increase in the incidence of renal failure from diabetic nephropathy. Nephron. 65(1): 160PubMedCrossRefGoogle Scholar
  17. Hasegawa G., Nakano K., Sawada M., Uno K., Shibayama Y., Lenaga K., Kondo M. (1991) Posslble role of tumor necrosls factor and interleukin 1 in the development of diabetic nephropathy. Kidney Int 40(6): 1007–1012PubMedCrossRefGoogle Scholar
  18. Hasslacher C., Borgholte G., Panradl U., Wahl P. (1990) Verbesserte Prognose von Typ 1 und Typ 2 Diabetikern mit Nephropathie. Med Klin 85: 643–646Google Scholar
  19. Hasslacher C., Bostedt Kiesel A., Kempe H.P., Wahl P. (1993) Effect of metabolie factors and blood pressure on kidney function in proteinuric type 2 (non insulin dependent) diabetic patients. Diabetologia 36(10): 1051–1056Google Scholar
  20. Heesom A.E., Hibberd M.L., Millward A., Demaine A.G. (1997) Polymorphism in the 5’ end of the aldose reduetase gene is strongly assoeiated with the development of diabetic nephropathy in type I diabetes. Diabetes 46(2): 287–291PubMedCrossRefGoogle Scholar
  21. Hoffman B., Ziyadeh Z. (1996) The role of growth facors in the development of diabetic nephropathy. Curr Opin Endocrinol Diab 3: 322–329CrossRefGoogle Scholar
  22. Horie K., Miyata T., Maeda K., Miyata S., Sugiyama S., Sakai H., van Ypserle de Strihou C., Monnier V., Witzturn I., Kurokawa K. (1997) Immunohistochemical colocalization of glyeoxidation poducts and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 100(12): 2995–3004PubMedCrossRefGoogle Scholar
  23. Isaka Y., Akagi Y., Ando Y., Imai E. (1997) Application of gene therapy to diabetic nephropathy. Kidney Int 52(60): 100–103Google Scholar
  24. Ishii H., Jirousek, M., Koya D. et al. (1996) Amelioration of vascular dysfunktion in diabetic rats by an oral PKC ß inhibitor. Science 27: 728–731CrossRefGoogle Scholar
  25. Jerums G., Allen T.I., Tsalamandris C., Cooper M.E. (1992) Angiotensin eonverting enzyme inhibition and calcium ehannel blockade in ineipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group. Kidney Int 41(4): 904–911PubMedCrossRefGoogle Scholar
  26. Jones S.C., Thomas G.H., Marshall S.M. (1997) Thiol group modulation of sodium lithium countertransport kinetics in diabetic nephropathy. Diabetologia 40: 1079–1084PubMedCrossRefGoogle Scholar
  27. Jungmann E. (1996) Chemoprophylaxis of diabetic nephropathy in the elderly. Drugs Aging 9(6): 449–457PubMedCrossRefGoogle Scholar
  28. Kagami S., Border W., Miller and Noble N. (1994) Angiotensin II stimulates extrazellular matrix protein synthesis through induction of transforming growth factor ß expression in rat glomerular mesangial cells. J Clin Invest June 13: 2431–2437Google Scholar
  29. Kennefick T., Anderson Z. (1997) Role of angiotensin II in diabetic nephropathy. Semin Nephrol 17(5): 441–447PubMedGoogle Scholar
  30. Kikkawa R., Togawa M., Isono M., Isshiki K., Haneda M. (1997) Mechanism of the progression of diabetic nephropahy to renal failure. Kidney Int 52(5): 39–40.Google Scholar
  31. Kramer B.K., Wiecek A., Ritz E. (1997) In what way and how mtensively should blood pressure be lowered in diabetic nephropathy? Dtsch Med Wochenschr 122(25, 26): 829–832PubMedCrossRefGoogle Scholar
  32. Krämer B.K., Wiecek A., Ritz E. (1997) Wieweit und wie intensiv soll der Blutdruck bei diabetiseher Nephropathie gesenkt werden? Dtsch Med Wochensehr 122: 829–832CrossRefGoogle Scholar
  33. Kramer Guth A, Quaschning T., Greiber S., Wanner C. (1996) Potential role of lipids in the progression of diabetic nephropathy. Clin Nephrol 46(4): 262–265Google Scholar
  34. Krolewski A.S., Laffel L.M., Krolewski M., Quinn M., Warram J.H. (1995) Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin dependent diabetes mellitus. N Engl J Med 332(19): 1251–1255PubMedCrossRefGoogle Scholar
  35. Lam K.S., Cheng I.K., Janus E.D., Pang R.W. (1995) Cholesterol lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 38(5):604–609.PubMedCrossRefGoogle Scholar
  36. Lash J.P., Bakris G.L. (1995) Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant 10 (Suppl. 9): 56–62PubMedGoogle Scholar
  37. Lewis E.I., Hunsicker L.G., Bain R.P., Rohde R.D. (1993) The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329(20): 1456–1462PubMedCrossRefGoogle Scholar
  38. Lippert I., Ritz E., Sehwarzbeck, A., Schneider P. (1995) The rising tide of endstage renal failure from diabetic nephropathy type II an epidemiological analysis (see comments). Nephrol Dial Transplant. 10(4): 462–467PubMedGoogle Scholar
  39. Makita Z., Yanagisawa K., Kuwajima S., Yoshioka N., Atsumi T., Hasunuma Y., Koike T. (1995) Advanced glycation endproducts and diabetic nephropathy. J Diabetes Complications 9(4): 265–268PubMedCrossRefGoogle Scholar
  40. Mangili R., Bending Z., Scott Z. (1988) Increased sodium lithium countertransport activity in red cells of patients with insulin dependent diabetes and nephropathy. N Engl J Med 318:146–150PubMedCrossRefGoogle Scholar
  41. Maschio G., Alberti D., Janin G. et al. (1996) Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group (see comments). N Engl J Med 334(15): 939–945PubMedCrossRefGoogle Scholar
  42. Mathiesen E.R., Hommel E., Giese I., Parving H.H. (1991) Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria (see comments). BMJ 303(6794): 81–87PubMedCrossRefGoogle Scholar
  43. Mogensen C.E. (1994) Renoprotective role of ACE inhibitors in diabetic nephropathy. Br Heart J 72(Suppl. 3): 38–45CrossRefGoogle Scholar
  44. Mogensen C.E., Damsgaard E.M., Froland A., Nielsen S., de Fine Olivarius N., Schmitz A. (1992) Microalbuminuria in non insulin dependent diabetes. Clin Nephrol 38 (Suppl. 1): 28–39Google Scholar
  45. Mogensen C.E., Hansen K.W., Nielsen S., Pedersen M.M., Rehling M., Schmitz A. (1993) Monitoring diabetic nephropathy: glomerular filtration rate and abnormal albuminuria in diabetic renal disease reproducibility, progression, and efficacy of antihypertensive intervention. Am J Kidney Dis 22(1): 174–187PubMedGoogle Scholar
  46. Molitch M.E. (1997) Management of early diabetic nephropathy. Am J Med 102: 392–398PubMedCrossRefGoogle Scholar
  47. Molitch M.E. (1994) ACE inhibitors and diabetic nephropathy. Diabetes Care 17(7): 756–760PubMedGoogle Scholar
  48. Moran A., Brown D.M., Kim Y., Klein D.J. (1991) Effects of IGF I and glucose on protein and proteoglycan synthesis by human fetal mesangial cells in culture. Diabetes 40(10): 1346–1354PubMedCrossRefGoogle Scholar
  49. Nelson R.G., Pettitt D.J., Baird H.R., Charles M.A., Liu Q.Z., Bennett P.H., Knowler W.C. (1993) Pre diabetic blood pressure predicts urinary albumin excretion after the onset of type 2 (non insulin dependent) diabetes mellitus in Pima Indians. Diabetologia 36(10): 998–1001PubMedCrossRefGoogle Scholar
  50. Nielsen F.S., Rossing P., Gall M.A., Skott P., Smidt U.M., Parving H.H. (1997) Long term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46(7): 1182–1188PubMedCrossRefGoogle Scholar
  51. O’Donneli M.I., Rowe B.R., Lawson N., Horton A., Gyde O.H., Barnett A.H. (1993) Placebo controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. J Hum Hypertens 7(4): 327–332Google Scholar
  52. Parving H., Tarnow L., Rosing P. (1996) The angiotensin converting enzyme gene and ist inhibition in diabetic nephropathy. Curr Opin Endocrin 3: 315–321CrossRefGoogle Scholar
  53. Parving H.H., Jacobsen P., Rossing K., Smidt U.M., Hommel E., Rossing P. (1996) Benefits of long term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 49(6): 1778–1782PubMedCrossRefGoogle Scholar
  54. Parving H.H., Smidt U.M., Hommel E., Mathiesen E.R., Rossing P., Nielsen F., Gall M.A. (1993) Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 22(1): 188–195PubMedGoogle Scholar
  55. Pugh J.A., Medina R., Ramirez M. (1993) Comparison of the course to end stage renal disease of type 1 (insulin dependent) and type 2 (non insulin dependent) diabetic nephropathy. Diabetologia 36(10): 1094–1098PubMedCrossRefGoogle Scholar
  56. Ravid O. (1993) Long term stabilizing effect of angiotensin converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Int Med 118: 577–581PubMedCrossRefGoogle Scholar
  57. Ringel I., Beige J., Kunz R., Distler A., Sharma A.M. (1997) Genetic variants of the renin angiotensin system, diabetic nephropathy and hypertension. Diabetologia 40(2): 193–199PubMedCrossRefGoogle Scholar
  58. Ritz E. (1993) Hypertension in diabetic nephropathy: Prevention and treatment. Am Heart J 125(5, P2): 1514–1519PubMedCrossRefGoogle Scholar
  59. Ritz E. (1997) Nephropathy in type II diabetes. Exp Clin Endocrinol Diab 105(Suppl): 80–82Google Scholar
  60. Ritz E., Bergis C., Strojek K., Keller C. (1997) Nephropathie und Hypertonie bei Typ 2 Diabetes. Med Klein 92: 421–425CrossRefGoogle Scholar
  61. Ritz E., Hasslacher C., Tschope W. (1990) Diabetic nephropathy are there differences between type I and type II? Miner Electrolyte Metabol 16(1): 69–72Google Scholar
  62. Ritz E., Keller C., Bergis K., Strojek K. (1997) Pathogenesis and course of renal disease in IDDM/NIDDM: differences and similarities. Am J Hypertens 10(9 Pt 2): 202S-207SGoogle Scholar
  63. Ritz E., Keller C., Bergis K.H. (1996) Nephropathy of type II diabetes mellitus. Nephrol Dial Transplant 11 (Suppl. 9): 38–44PubMedCrossRefGoogle Scholar
  64. Ritz E., Orth S.R., Strzelczyk P. (1997) Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. J Hypertens (Suppl.) 15(2): 21–26Google Scholar
  65. Ritz E., Siebeis M., Fliser D. (1993) Hemmung der Progression der Niereninsuffizienz bei glomerulären Erkrankungen. Internist 34: 330–339PubMedGoogle Scholar
  66. Ritz E., Stefanski A. (1996) Diabetic nephropathy in type II diabetes. Am J Kidney Dis 27/2: 167–194CrossRefGoogle Scholar
  67. Ritz E., Keller C., Bergis K. (1996) Nephropathy of type II diabetes mellitus. Nephrology Dialysis Transplantation 11 Suppl 9: 38–44. ReviewCrossRefGoogle Scholar
  68. Rutherford P.A., Thomas T.H., Taylor R., Wilkinson R. (1994) Nephropathy and changes in sodium lithium countertransport kinetics in type 2 (non insulin dependent) diabetes mellitus. J Hum Hypertens 8(1): 29–35PubMedGoogle Scholar
  69. Salahudeen A.K., Kanji V., Reckelhoff J.F., Schmidt A.M. (1997) Pathogenesis of diabetic nephropathy: a radical approach. Nephrol Dial Transplant 12(4): 664–668PubMedCrossRefGoogle Scholar
  70. Sawicki P.T. (1997) Stabilization of glomerular filtration rate over 2 years in patients with diabetic nephropathy under intensified therapy regimes. Nephrol Dial Transplant 12: 1890–1899PubMedCrossRefGoogle Scholar
  71. Sawicki P.T., Dahne R., Bender R., Berger M. (1996) Prolonged QT interval as a predictor of mortality in diabetic nephropathy. Diabetologia 39(1): 77–81PubMedGoogle Scholar
  72. Sawicki P.T., Muhlhauser I., Didjurgeit U., Baumgartner A., Sender R., Berger M. (1995) Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy. J Hypertens 13(8): 933–938PubMedCrossRefGoogle Scholar
  73. Schmidt A., Hasu M., Popov D. et al. (1998) Receptor for advanced glyeation end produets (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA:8807–8811Google Scholar
  74. Schmidt S., Giessel R., Bergis K.H., Strojek K., Grzeszczak W., Ganten D., Ritz E. (1996) Angiotensinogen gene M235 T polymorphism is not associated with diabetic nephropathy. The Diabetic Nephropathy Study Group. Nephrol Dial Transplant 11(9): 1755–1761PubMedCrossRefGoogle Scholar
  75. Schmidt S., Ritz E. (1996) The role of angiotensin I converting enzyme gene polymorphism in renal disease. Curr Opin Nephrol Hypertens 5(6): 552–555CrossRefGoogle Scholar
  76. Schmidt S., Strojek K., Grzeszczak W., Bergis K., Ritz E. (1997) Excess of DD homozygotes in haemodialysed patients with type II diabetes. The Diabetic Nephropathy Study Group. Nephrol Dial Transplant 12(3): 427–429PubMedCrossRefGoogle Scholar
  77. Sensi M., Pricci F., Andreani D., Di Mario U. (1991) Advanced nonenzymatic glycation endproducts (AGE): Their relevance to aging and the pathogenesis of late diabetic complications. Diabetes Res 16: 1–9PubMedGoogle Scholar
  78. Shikata K., Makino H., Sugimoto H. et al. (1995) Localization of advanced glycation endproducts in the kidney of experimental diabetic rats. J Diabetes Complications 9(4): 269–271PubMedCrossRefGoogle Scholar
  79. Smulders Y., Rakic M., Stehouwer C., Weijers R., Slaats E., Silberbusch J. (1997) Determinants of progression of microalbuminuria in patients with NIDDM. Diabetes Care 20(6): 999–1003PubMedCrossRefGoogle Scholar
  80. Soulis T., Cooper M.E., Vranes D., Bueala R., Jerums G. (1996) Effects of aminoguanidine in preventing experimental diabetie nephropathy are related to the duration of treatment. Kidney Int 5072: 627–634CrossRefGoogle Scholar
  81. Stephenson Z. et a!. (1994) The EURODIAB IDDM Complications study. Diabetologia 37: 278–285CrossRefGoogle Scholar
  82. Striker L.I., Striker G.E. (1996) Administration of AGEs in vivo in duces extracellular matrix gene expression. N ephrol Dial Transplant 11(Suppl. 5): 62–65CrossRefGoogle Scholar
  83. Strojek K., Grzeszczak G., Ritz E. (1997) Risk factors for development of diabetic nephropathy: A review. Nephrol Dial Transplant 12(Suppl. 2): 24–26PubMedGoogle Scholar
  84. Strojek K., Grzeszczak W., Morawin E. et al. (1997) Nephropathy of type II diabetes: evidence for hereditary factors? Kidney Int 51(5): 1602–1607PubMedCrossRefGoogle Scholar
  85. Tamsma J.T., van den Born I., Bruijn J.A. et al. (1994) Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease ofheparan sulphate in the glomerular basement membrane (see comments). Diabetologia 37(3): 313–320PubMedCrossRefGoogle Scholar
  86. Tamsma J.T., van der Woude F.I., Lemkes H.H. (1996) Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type I) nephropathy. N ephrol Dial Transplant 11(1): 182–185CrossRefGoogle Scholar
  87. Tepel M., Doberauer C., Zidek W. (1997) Diabetic nephropathy and genetic alterations of the renin angiotensin system. Exp Clin Endocrinol Diabetes 105/5: 243–247CrossRefGoogle Scholar
  88. Tepel M., van Giet M., Zidek M. (1997) Praktische Therapie der chronischen Niereninsuffizienz durch Progressionshemmung. Dtsch Arzteblatt 94(41): 2161–2166Google Scholar
  89. Thaiss F., Stahl R.A. (1996) The kidney in diabetes mellitus new aspeets on pathogenesis, diagnosis and therapy. Z Arztl Fortbild Jena 90(3): 199–204PubMedGoogle Scholar
  90. The Diabetes Control and Complications Trial (OCCT) Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 329: 14–18CrossRefGoogle Scholar
  91. The Diabetes Control and Complications Trial (DCCT) Research Group (1995) The effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47(6): 1703–1720CrossRefGoogle Scholar
  92. The Diabetes Control and Complications Trial Research Group (1996) Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complicqations trial. JAMA 276(17): 1409–1415CrossRefGoogle Scholar
  93. Tripathi K., Prakash I., Appaiha D., Srivasta P. (1993) Pentoxyfylline in management of proteinuria in diabetic nephropathy. Nephron 64: 641–642PubMedCrossRefGoogle Scholar
  94. United kingdom Prospeetive Diabetes Study Group (1998) United Kingdom Prospective Diabetes Study 24: A 6 year, randomized, controlled trial comparing sulfonylurea, insulin and metformin therapy in patients with newly diagnosed type 2 diabetes that eould not be controlled with diet therapy. Ann Intern Med 128(3): 165–175CrossRefGoogle Scholar
  95. United kingdom Prospective Diabetes Study Group (1998) Effect of intensive blood glucose control with metformin on omplications in overweight patients with type 2 diabetes. Lancet 352: 854–864CrossRefGoogle Scholar
  96. United Kingdom Prospective Diabetes Study Group (1998) Efficiacy of atenolol and captopril in reducing risk of miacrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 317: 13–26,713-726CrossRefGoogle Scholar
  97. United Kingdom Prospective Diabetes Study Group (1998) Intensive blood glucose control with sulfonylureas ur insulin compared with conventional treatment and risk of compliations in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853CrossRefGoogle Scholar
  98. Van der Woude F., van Oet N.F. (1997) Heparan suäphate proteoglycans and diabetic nephropathy. Exp Nephrol 5: 180–188PubMedGoogle Scholar
  99. Van der Woude F.I., van Det N.F. (1997) Heparan sulphate proteoglycans and diabetic nephropathy. Exp Nephrol 5(3): 180–188PubMedGoogle Scholar
  100. Vlassara H. (1995) Advanced glycation in diabetic renal and vascular disease. Kidney Int 51(Suppl.): 43–44Google Scholar
  101. Vlassara H. (1997) Pathogenesis of diabetic nephropathy, advanced glycation and new therapy. Med Klin 92(Suppl.): 29–34CrossRefGoogle Scholar
  102. Vlassara H., Striker L.I., Teichberg S., Fuh H., Li Y.M., Steffes M. (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91(24): 11704–11708PubMedCrossRefGoogle Scholar
  103. Wainai H., Katsukawa F., Takei I., Maruyama H., Kataoka K., Saruta T. (1991) Influence of glycemic control and hypertension on urinary microprotein excretion in non insulin dependent diabetes mellitus. J Diabet Compl 5(2-3): 160–161CrossRefGoogle Scholar
  104. Waldherr R., Ilkenhans C., Ritz E. (1992) How frequent is glomerulonephritis in diabetes mellitus type II? Clin Nephrol 378(6): 271–273Google Scholar
  105. Wolf G., Neilson E.G. (1993) Angiotensin II as aa hypertrophogenic cytokine for proximal tubular cells. Kidney Int 43: 100–107Google Scholar
  106. Wolf G., Ziyadeh F., Thaiss F. et al. (1997) Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. J Clin Invest 100(5): 1047–1058PubMedCrossRefGoogle Scholar
  107. Wolf G., Ziyadeh F.N. (1997) The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 29(1): 153–163PubMedCrossRefGoogle Scholar
  108. Wolf G., Ziyadeh F.N., Zahner G., Stahl R.A. (1996) Angiotensin II is mitogenic for cultured rat glomerular endothelial cells. Hypertension 27(4): 897–905PubMedCrossRefGoogle Scholar
  109. Wolf S., Stahl R. (1996) Angiotensin II Wirkulg an der Niere: mehr als ein Vasokonstriktor. Dtsch Arzetebl 31(32): 1604–1608Google Scholar
  110. Yang C.W., Vlassara H., Peten E.P., He C.I., Striker G.E., Striker L.J. (1994) Advanced glycation end products up regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 91(20): 9436–9440PubMedCrossRefGoogle Scholar
  111. Yokoyama H., Tomonaga O., Hirayama M. et al. (1997) Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin converting enzyme inhibitors in NIDDM patients. Diabetologia 40(4): 405–411PubMedCrossRefGoogle Scholar
  112. Zeller K., Whittaker E., Sullivan L., Raskin P., Jacobson H.R. (1991) Effect of restricting dietary protein on the progression of renal failure in patients with insulin dependent diabetes mellitus. N Engl J Med 324(2): 78–84PubMedCrossRefGoogle Scholar
  113. Ziyadeh F., Snipes E., Watanabe M., Alvarez R., Goldfarb, Haverty T. (1990) High glucose in duces cell hypertrophy and stimulates collagen gene transcription in proximale tubule. Am J Phys 259(4 Pt 2): F704–714Google Scholar

Literatur zu Abschn. 16.14

  1. Anand P., Terenghi G., Warner G., Kopelman P., Williams-Chestnut R.E., Sinicropi D.V. (1996) The role of endogenous nerve growth factor in human diabetic neuropathy. Nature Medicine 6: 703–707CrossRefGoogle Scholar
  2. Clark C.M., Lee D.A. (1995) Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 332: 1210–1217PubMedCrossRefGoogle Scholar
  3. DCCT study group (1995) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 Sep 30; 329(14): 977–986CrossRefGoogle Scholar
  4. Erckenbrecht J.F,. Flesch S., Frieling T., Ziegler D., Wienbeck M., Caspary W. (1996) Die autonome diabetische Neuropathie des Gastrointestinaltraktes. Dtsch Arzteblatt 93: 1436–1440Google Scholar
  5. Flynn M.D., O’Brien I.A., Corrall R.J.M. (1995) The prevalence of autonomic and peripheral neuropathy in insulin treated diabetic subjects. Diabetic Medicine 12: 310–313PubMedCrossRefGoogle Scholar
  6. Frolich I., Blum-Degen D. et al. (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neural Transm. 105(4-5): 423–438PubMedCrossRefGoogle Scholar
  7. Heitner J. und Dickson D. (1997) Diabetics do not have increased Alzheimer-type pathology compared with age matched control subjects. A retrospective postmortem immuncytochemical and histoflurescent study. Neurology 49(5): 1306–1311.PubMedCrossRefGoogle Scholar
  8. Itagaki T., Itoh Y., Sugai Y., Suematsu N., Ohtomo E., Yamada M. (1996) Glucose metabolism and Alzheimer’s dementia. Nippon-Ronen-Igakkai-Zasshi 8: 569–572CrossRefGoogle Scholar
  9. Leibson C.L., Rocca W.A., Hanson V.A., Cha R., Kokmen E., O’Brien P.C., Palumbo P.J. (1997) Risk of dementia Among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145(4): 301–308PubMedCrossRefGoogle Scholar
  10. Nagamatsu H., Nickander K., Schmelzer J., Raya A., Wittrock D., Tritschler H., Low P. (1995) Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18: 1160–1167PubMedCrossRefGoogle Scholar
  11. Nusser J., Landgraf R. (1990) Autonome Neuropathie bei Diabetes mellitus: Bedeutung in Klinik und Praxis. Internist 31: 198–207PubMedGoogle Scholar
  12. O’Brien I.A., McFadden J.P., Corrall R.J. (1991) The influence of autonomic neuropathy on mortality in insulin dependent diabetes. Q J Med. 79(290): 495–502PubMedGoogle Scholar
  13. O’Brien I.A., McFadden J.P., Corall R.J.M. (1991) The influence of autonomic neuropathy on mortality in insulin-dependent diabetics. Q J Med 290: 495–502Google Scholar
  14. Ott A., Stolk R.P., Hofmann A., van Harskamp F., Grobbee D.E., Breteler M.M. (1996). Association of diabetes mellitus and dementia: Rotterdam Study. Diabetologia 39(11): 1392–1397PubMedCrossRefGoogle Scholar
  15. Preiß R., Teicher J., Preiß C., Kern J., Tritschler H.J., Ulrich H. (1996) Untersuchungen zur Pharmakokinetik von alpha Liponsäure (Thioctsäure) an Patienten mit diabetischer Polyneuropathie. Diabetes Stoffw (Suppl. 5): 17–22Google Scholar
  16. Price D.E., Gingell J.C., Gepi-Attee S., Wareham K., Jates P., Boolell M. (1998). Sildenafil: Study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 15(10): 821–825PubMedCrossRefGoogle Scholar
  17. Sasaki N., Fukatsu R., Tsuzuki K. et al. (1998). Advanced glycation end products in alzheimer’s disease and other neurodegenerative diseases. Am J Pathol. 153(4): 1149–1155PubMedCrossRefGoogle Scholar
  18. Schmidt A.M. (1995) The dark side of glucose. Nature Medicine 1: 1002–1004PubMedCrossRefGoogle Scholar
  19. Stracke H., Lindemann A., Federlin K. (1996) Benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Endocrinol Diabetes 104: 311–316CrossRefGoogle Scholar
  20. The Diabetes Control and Complication Trial Research Group (1993) The effect of intensive treatment on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329: 977–986CrossRefGoogle Scholar
  21. Yan S.D., Chen X., Fu C. et al. (1996) RAGE and amyloid-β peptide neurotoxicity in Alzheimers disease. Nature 382: 685–691PubMedCrossRefGoogle Scholar
  22. Ziegler D., Hanefeld M., Ruhnau K.J. et al. (1995) Diabetologia 388: 1425–1433CrossRefGoogle Scholar

Literatur zu Abschn. 16.15

  1. Chantelau E., Tanudjaja T., Altenhöfer F., Ersanli Z., Lacigova S., Metzger C. (1996) Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diabet Med 13: 156–159PubMedCrossRefGoogle Scholar
  2. Forst T., Pfützner A., Kann P., Lobmann R., Schäfer H., Beyer J. (1995) Association between diabetic-autonomic c-fibre neuropathy and medial wall calcification and the significance m the outcome oftrophic foot lesions exp. Clin Endocrinol Diabetes 103: 94–98CrossRefGoogle Scholar
  3. Greenhalgh D.G., Sprugel K.H., Murray M.J., Ross R. (1990) PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Path 136: 1235–1245PubMedGoogle Scholar
  4. Li Y.M., Tan A.X., Vlassara H. (1995) Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nature Medicine 10: 1057–1061CrossRefGoogle Scholar
  5. Reike H. (1995) Das diabetische Fußsyndrom. Edition Materia Medica, S 52–53Google Scholar
  6. Sapico F.L., Witte J.L., Canawati H.N. et al. (1980) Quantitative aerobic and an aerobic biology of infected diabetic feet. J Clin Microbiol 12: 413PubMedGoogle Scholar
  7. Schmidt A.M., Yan S.D., Stern D. (1995) The dark side of glucose. Nature Medicine 10: 1002–1004CrossRefGoogle Scholar
  8. Trautner C., Haastert B., Giani G., Berger M. (1996) Incidence of lower limb amputations and diabetes. Diabetes Care 19(9): 1006–1009PubMedCrossRefGoogle Scholar

Literatur zu Abschn. 16.16

  1. Bolli G., De Feo P., Compagnucci P., Cartechini M.G., Angeletti G., Santeusanio F. (1983) Abnormal glucose counter-regulation in insulin-dependent diabetes mellitus: interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 32: 134–141PubMedCrossRefGoogle Scholar
  2. Bottini P., Boschetti E., Pampanelli S. et al. (1997) Contribution of autonomic neuropathy to reduced plasma adrenaline responses to hypoglycemia in IDDM: evidence for a non-selective defect. Diabetes 46: 814–823PubMedCrossRefGoogle Scholar
  3. Clarke W.L., Cox D.J., Gonder-Frederick L.A., Julian D., Schlundt D., Polonsky W., (1995) Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and assoclated symptoms. Diabetes Care 18: 517–522PubMedCrossRefGoogle Scholar
  4. Clarke W.L., Haymond M.W., Santiago J.V. (1980) Overnight basal insulin requirements in fasting insulin-dependent diabetics Diabetes 29: 78–80Google Scholar
  5. Cox D., Gonder-Frederick L., Polonsky W., Schlundt D., Julian D., Clarke W. (1995) A multicenter evaluation of blood glucose awareness training-II. Diabetes Care 18: 523–528PubMedCrossRefGoogle Scholar
  6. Cryer P.E. (1992a) Glucose homeostasis and hypoglycemia. In: Wilson J.D., Foster D.W. (eds) Williams textbook of endocrinology, 8th ed. Philadelphia, Saunders, pp 1223–1253Google Scholar
  7. Cryer P.E. (1992b). Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM: a vicious circle. Diabetes 41: 255–260PubMedCrossRefGoogle Scholar
  8. Cryer P.E. (1993). Hypoglycemia unawareness in IDDM. Diabetes Care 16: 40–47PubMedGoogle Scholar
  9. Cryer P.E., Frier B.M. (1997) Hypoglycaemia. In: Alberti K.G.M.M., Zimmet P., DeFronzo R.A., Keen H. (eds) International textbook of diabetes mellitus. 2nd edn, Wiley, pp 1193–1213Google Scholar
  10. Dagogo-Jack S.E., Craft S., Cryer P.E. (1993) Hypoglycemia-associated autonomic failure in insulin dependent diabetes mellitus. J Clin Invest 91: 819–828PubMedCrossRefGoogle Scholar
  11. Dagogo-Jack S., Rattarasarn C., Cryer P.E. (1994) Reversal ofhypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 43: 1426–1434PubMedCrossRefGoogle Scholar
  12. Fanelli C.G., Epifano L., Rambotti A.M. et al. (1993) Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intesively treated patients with shortterm IDDM. Diabetes 42: 1683–1689PubMedCrossRefGoogle Scholar
  13. Fanelli C., Pampanelli S., Epifano L. et al. (1994) Long-term recovery trom unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycemia, following institution of a rationale, intensive insulin therapy in IDDM. Diabetologia 37: 1265–1276PubMedCrossRefGoogle Scholar
  14. Fanelli C., Pampanelli S., Calderone S. et al. (1995) Effects of recent, short-term hyperglycemia on responses to hypoglycemia in humans. Relevance to the pathogenesis of hypoglycemia unawareness and hyperglycemia-induced insulin resistance. Diabetes 44: 513–519PubMedCrossRefGoogle Scholar
  15. Fukuda M., Tanaka A., Tahara Y., Ikegami H., Yamamoto Y., Kumahara Y., Shima K. (1988) Correlation between minimal secretory capacity of pancreatic β-cells and stability of diabetic control. Diabetes 37: 81–88PubMedCrossRefGoogle Scholar
  16. Gold A.E., MacLeod K.M., Frier B.M. (1994) Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness ofhypoglycemia. Diabetes Care 17: 697–703PubMedCrossRefGoogle Scholar
  17. Pramming S., Thorsteinsson B., Bendtson I., Binder C. (1991) Symptomatic hypoglycemia in 411 type 1 diabetic patients. Diabet Med 8: 217–222PubMedCrossRefGoogle Scholar
  18. Hepburn D.A., Patrick A.W., Eadington D.W., Ewing D.J., Frier B.M. (1990) Unawareness of hypoglycemia in insulin-treated diabetic patients: prevalence and relationship to autonomic neuropathy. Diabet Med 7: 711–717PubMedCrossRefGoogle Scholar
  19. Kalimo H., Olsson Y. (1980) Effects of severe hypoglycemia on the human brain. Acta Neurol Scand 62: 345–348PubMedCrossRefGoogle Scholar
  20. Lingenfelser T., Overkamp D., Renn W., Buettner U., Kimmerle K., Schmalfuss A., Jakober B. (1996) Insulin-associated modulation of neuroendocrine counterregulation, hypoglycemia perception, and cerebral function in insulin-dependent diabetes mellitus: evidence for an intrinsic effect of insulin on the central nervous system. J Clin Endocrinol Metab 81: 1197–1205PubMedCrossRefGoogle Scholar
  21. Liu D., McManus R.M., Ryan E.A. (1996) Improved counter-regulatory hormonal and symptomatic responses to hypoglycemia in patients with insulin-dependent diabetes mellitus after 3 months of less striet glycemic controL. Clin Invest Med 19: 71–82PubMedGoogle Scholar
  22. Mokan M., Mitrakou A., Veneman T., Ryan C., Korytowski M., Cryer P., Gerich J. (1994) Hypoglycemia unawareness in IDDM. Diabetes Care 17: 1397–1403PubMedCrossRefGoogle Scholar
  23. Service F.J. (1995) Hypoglycemic disorders. N Engl J Med 332: 1144–1152PubMedCrossRefGoogle Scholar
  24. Tattersall R.B., Gill G.V. (1991) Unexplained deaths of type 1 diabetic patients. Diabet Med 8: 49–58PubMedCrossRefGoogle Scholar
  25. The Diabetes Control and Complications Trial Research Group (I993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986Google Scholar
  26. Turnbridge W.M.G. (1981) Factors contributing to deaths of diabetics under fifty years of age. Lancet 569–572Google Scholar
  27. Veneman T.F., Van Haeften T.W. (1994) Hypoglycemia unawareness in insulin-dependent diabetes mellitus. Europ J Clin luvest 24: 785–793CrossRefGoogle Scholar
  28. White N.H., Skor D.A., Cryer P.E., Levandoski L., Bier D.M., Santiago J.V. (1983) Identification of type 1 diabetic patients at increased risk for hypoglycemia during intensive therapy. New Engl J Med 308: 485–491PubMedCrossRefGoogle Scholar

Literatur zu Abschn. 16.17

  1. Aydin S., Odabas O., Ercan M., Kara H., Agargun M.Y. (1996) Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. Br J Urol 77: 256–260PubMedCrossRefGoogle Scholar
  2. Buvat I., Lemaire A., Buvat-Herbaut M. (1985) Comparative investigations in 26 impotent and 26 nonimpotent diabetic patients. J Urol 133: 34–38PubMedGoogle Scholar
  3. Chen R.N., Lakin M.M., Montague D.K., Ausmundson S. (1996) Penile scarring with intracavernous injection therapy using prostagiandin El: a risk factor analysis. J Urol 155: 138–140PubMedCrossRefGoogle Scholar
  4. Hirshkowitz M., Karaean I., Rando K.C., Williams R.L., Howell J.W. (1990) Diabetes, erectile dysfunction, and sleep-related erections. Sleep 13(1): 53–68PubMedGoogle Scholar
  5. Jensen S.B. (1986) Sexual dysfunction in insulin-treated diabetics: a six-year follow-up study of 101 patients. Arch Sex Behav 15(4): 271–283PubMedCrossRefGoogle Scholar
  6. Kerfoot W.W., Carson C.C., Donaldson J.T., Kliewer M.A. (1994) Investigation of vascular changes following penile vein ligation. J Urol 152: 884–887PubMedGoogle Scholar
  7. Klein R., Klein B.E., Lee K.E., Moss S.E., Cruickshanks K.J. (1995) Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care 19: 135–141CrossRefGoogle Scholar
  8. Knoll L.D., Benson R.C. Jr, Bilhartz D.L., Minich P.I., Furlow W.L. (1996) A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence. J Urol 155: 144–146PubMedCrossRefGoogle Scholar
  9. Korenman L.G., Lue T.F. (1994) Erectile Dysfunction. Current concepts. Pharmaeia & UpjohnGoogle Scholar
  10. Lineoln I., Crowe R., Blacklay P.F., Pryor J.P., Lumley J.S., Burnstock G. (1987) Changes in the vipergic, cholinergic and adrenergic innervation of human penile tissue in diabetic and non-diabetic impotent males. J Urol 137: 1053–1059Google Scholar
  11. Linet O., Ogrine F.G. (1996) Efficacy and safety of intraeavernosal alprostadil in men with erectile dysfunction. N Engl J Med 334: 873–877PubMedCrossRefGoogle Scholar
  12. McCulloch, Campbell I.W, Wu F.C., Prescott R.J., Clarke B.F. (1980) The prevalence of diabetie impotence. Diabetologia 18: 279–283Google Scholar
  13. Melman A., Henry D. (1979) The possible role of the catecholamines of the corpora in penile erection. J Urol 121(4): 419–421PubMedGoogle Scholar
  14. Robinson A.M., Ryder R.E.J. (1991) Impotence in diabetes. Trends Endoerinol Metab 8: 98–101CrossRefGoogle Scholar
  15. Ryder R.E., Close C.F., Moriarty K.T., Moore K.T., Hardisty C.A. (1992) Impotence in diabetes: aetiology, implications for treatment and preferred vaeuum device. Diabet Med 9: 893–898PubMedCrossRefGoogle Scholar
  16. Saenz de Tejada I., Goldstein I., Azadzoi K., Krane R.J., Cohen R.A. (1989) Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 320: 1025–1030CrossRefGoogle Scholar
  17. Treiber U., Gilbert P. (1989) Venous surgery in erectile dysfunction: a critical report on 116 patients. Urology 34(1): 22–27CrossRefGoogle Scholar
  18. Turner L.A., Althof S.E., Levine S.B., Tobias I.R., Kursh E.D., Bodner D., Resnick M.L. (1990) Treating erectile dysfunction with extern al vacuum devices: impact upon sexual, psychological and mari tal functions. J Urol 144: 79–82PubMedGoogle Scholar
  19. Vale J.A., Feneley M.R., Lees W.R., Kirba R.S. (1995) Venous leak surgery: long-term follow-up of patients undergoing excision and Iigation of the deep dorsal vein of the penis. Br J Urol 76: 192–195PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • M. Brado
  • A. Bierhaus
  • A. Clemens
  • K. Dugi
  • M. Haass
  • H.-P. Hammes
  • A. v. Herbay
  • M. Hofmann
  • B. Isermann
  • T. Kassessinoff
  • M. S. Klevesath
  • G. Klöppel
  • M. Morcos
  • P. P. Nawroth
  • R. Riedasch
  • P. Rösen
  • S. Schiekofer
  • P. Wahl
  • T. Weiss

There are no affiliations available

Personalised recommendations